USUBJID,SITE,SITEID,AGE,SEX,RACE,ARM,ARMCD,SBJTSTAT,RFSTDTC,RFENDTC,RFENDY,SAFFL,SAFFN,RANDDT,RANDDY,COMPLDT,COMPLDY,ANYAEFL,ANYCMFL,AVISIT,AVISITN,ADT,ADY,CNSRDT,CNSRDY,ADUR,PARAMCAT,PARAM,AVALC,AVAL,ACOLOR
01-002,Clinical Site 01,1,24,F,Black,Treatment A,TRTA,Ongoing,2015-05-30,2015-11-09,164,Y,1,2015-07-29,61,2016-05-29,366,Y,N,Screening,0,2015-05-30,1,2015-12-07,192,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-002,Clinical Site 01,1,24,F,Black,Treatment A,TRTA,Ongoing,2015-05-30,2015-11-09,164,Y,1,2015-07-29,61,2016-05-29,366,Y,N,Screening,0,2015-05-30,1,2015-12-07,192,108,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-002,Clinical Site 01,1,24,F,Black,Treatment A,TRTA,Ongoing,2015-05-30,2015-11-09,164,Y,1,2015-07-29,61,2016-05-29,366,Y,N,Visit 2,2,2015-09-15,109,2015-12-07,192,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
01-002,Clinical Site 01,1,24,F,Black,Treatment A,TRTA,Ongoing,2015-05-30,2015-11-09,164,Y,1,2015-07-29,61,2016-05-29,366,Y,N,Visit 2,2,2015-09-15,109,2015-12-07,192,52,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-002,Clinical Site 01,1,24,F,Black,Treatment A,TRTA,Ongoing,2015-05-30,2015-11-09,164,Y,1,2015-07-29,61,2016-05-29,366,Y,N,Visit 3,3,2015-11-06,161,2015-12-07,192,31,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-003,Clinical Site 01,1,43,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-08-13,2016-02-23,195,Y,1,2015-10-04,53,2016-08-18,372,Y,Y,Screening,0,2015-08-13,1,2016-02-15,187,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-003,Clinical Site 01,1,43,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-08-13,2016-02-23,195,Y,1,2015-10-04,53,2016-08-18,372,Y,Y,Screening,0,2015-08-13,1,2016-02-15,187,54,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-003,Clinical Site 01,1,43,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-08-13,2016-02-23,195,Y,1,2015-10-04,53,2016-08-18,372,Y,Y,Visit 1,1,2015-10-06,55,2016-02-15,187,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
01-003,Clinical Site 01,1,43,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-08-13,2016-02-23,195,Y,1,2015-10-04,53,2016-08-18,372,Y,Y,Visit 1,1,2015-10-06,55,2016-02-15,187,59,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-003,Clinical Site 01,1,43,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-08-13,2016-02-23,195,Y,1,2015-10-04,53,2016-08-18,372,Y,Y,Visit 2,2,2015-12-04,114,2016-02-15,187,73,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-004,Clinical Site 01,1,42,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-01-12,2015-04-26,105,Y,1,2015-03-02,50,2016-01-05,359,N,Y,Screening,0,2015-01-12,1,2015-03-14,62,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-004,Clinical Site 01,1,42,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-01-12,2015-04-26,105,Y,1,2015-03-02,50,2016-01-05,359,N,Y,Screening,0,2015-01-12,1,2015-03-14,62,61,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-005,Clinical Site 01,1,51,M,White,Treatment B,TRTB,Ongoing,2015-11-11,2016-03-18,129,Y,1,2016-01-01,52,2016-11-18,374,Y,N,Screening,0,2015-11-11,1,2016-03-14,125,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-005,Clinical Site 01,1,51,M,White,Treatment B,TRTB,Ongoing,2015-11-11,2016-03-18,129,Y,1,2016-01-01,52,2016-11-18,374,Y,N,Screening,0,2015-11-11,1,2016-03-14,125,52,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-005,Clinical Site 01,1,51,M,White,Treatment B,TRTB,Ongoing,2015-11-11,2016-03-18,129,Y,1,2016-01-01,52,2016-11-18,374,Y,N,Visit 1,1,2016-01-02,53,2016-03-14,125,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-005,Clinical Site 01,1,51,M,White,Treatment B,TRTB,Ongoing,2015-11-11,2016-03-18,129,Y,1,2016-01-01,52,2016-11-18,374,Y,N,Visit 1,1,2016-01-02,53,2016-03-14,125,72,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-008,Clinical Site 01,1,53,F,Black,Treatment B,TRTB,Ongoing,2015-11-21,2015-12-05,15,Y,1,2016-01-08,49,2016-11-14,360,Y,N,Screening,0,2015-11-21,1,2015-12-22,32,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-008,Clinical Site 01,1,53,F,Black,Treatment B,TRTB,Ongoing,2015-11-21,2015-12-05,15,Y,1,2016-01-08,49,2016-11-14,360,Y,N,Screening,0,2015-11-21,1,2015-12-22,32,31,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-009,Clinical Site 01,1,44,M,White,Treatment B,TRTB,Ongoing,2015-11-25,2016-05-07,165,Y,1,2016-01-24,61,2016-11-29,371,Y,Y,Screening,0,2015-11-25,1,2016-06-08,197,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-009,Clinical Site 01,1,44,M,White,Treatment B,TRTB,Ongoing,2015-11-25,2016-05-07,165,Y,1,2016-01-24,61,2016-11-29,371,Y,Y,Screening,0,2015-11-25,1,2016-06-08,197,114,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-009,Clinical Site 01,1,44,M,White,Treatment B,TRTB,Ongoing,2015-11-25,2016-05-07,165,Y,1,2016-01-24,61,2016-11-29,371,Y,Y,Visit 2,2,2016-03-18,115,2016-06-08,197,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-009,Clinical Site 01,1,44,M,White,Treatment B,TRTB,Ongoing,2015-11-25,2016-05-07,165,Y,1,2016-01-24,61,2016-11-29,371,Y,Y,Visit 2,2,2016-03-18,115,2016-06-08,197,49,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-009,Clinical Site 01,1,44,M,White,Treatment B,TRTB,Ongoing,2015-11-25,2016-05-07,165,Y,1,2016-01-24,61,2016-11-29,371,Y,Y,Visit 3,3,2016-05-06,164,2016-06-08,197,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
01-009,Clinical Site 01,1,44,M,White,Treatment B,TRTB,Ongoing,2015-11-25,2016-05-07,165,Y,1,2016-01-24,61,2016-11-29,371,Y,Y,Visit 3,3,2016-05-06,164,2016-06-08,197,33,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-010,Clinical Site 01,1,35,F,Black,Treatment B,TRTB,Ongoing,2015-01-06,2015-05-04,119,Y,1,2015-02-23,49,2016-01-10,370,N,N,Screening,0,2015-01-06,1,2015-07-08,184,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-010,Clinical Site 01,1,35,F,Black,Treatment B,TRTB,Ongoing,2015-01-06,2015-05-04,119,Y,1,2015-02-23,49,2016-01-10,370,N,N,Screening,0,2015-01-06,1,2015-07-08,184,51,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-010,Clinical Site 01,1,35,F,Black,Treatment B,TRTB,Ongoing,2015-01-06,2015-05-04,119,Y,1,2015-02-23,49,2016-01-10,370,N,N,Visit 1,1,2015-02-26,52,2015-07-08,184,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
01-010,Clinical Site 01,1,35,F,Black,Treatment B,TRTB,Ongoing,2015-01-06,2015-05-04,119,Y,1,2015-02-23,49,2016-01-10,370,N,N,Visit 1,1,2015-02-26,52,2015-07-08,184,61,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-010,Clinical Site 01,1,35,F,Black,Treatment B,TRTB,Ongoing,2015-01-06,2015-05-04,119,Y,1,2015-02-23,49,2016-01-10,370,N,N,Visit 2,2,2015-04-28,113,2015-07-08,184,71,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
01-011,Clinical Site 01,1,33,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-10-04,2016-01-23,112,Y,1,2015-11-30,58,2016-09-26,359,Y,N,Screening,0,2015-10-04,1,2016-01-16,105,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-011,Clinical Site 01,1,33,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-10-04,2016-01-23,112,Y,1,2015-11-30,58,2016-09-26,359,Y,N,Screening,0,2015-10-04,1,2016-01-16,105,104,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-012,Clinical Site 01,1,36,M,White,Placebo,PLACEBO,Ongoing,2015-04-18,2015-12-21,248,Y,1,2015-06-06,50,2016-04-26,375,N,Y,Screening,0,2015-04-18,1,2015-10-19,185,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-012,Clinical Site 01,1,36,M,White,Placebo,PLACEBO,Ongoing,2015-04-18,2015-12-21,248,Y,1,2015-06-06,50,2016-04-26,375,N,Y,Screening,0,2015-04-18,1,2015-10-19,185,54,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-012,Clinical Site 01,1,36,M,White,Placebo,PLACEBO,Ongoing,2015-04-18,2015-12-21,248,Y,1,2015-06-06,50,2016-04-26,375,N,Y,Visit 1,1,2015-06-11,55,2015-10-19,185,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
01-012,Clinical Site 01,1,36,M,White,Placebo,PLACEBO,Ongoing,2015-04-18,2015-12-21,248,Y,1,2015-06-06,50,2016-04-26,375,N,Y,Visit 1,1,2015-06-11,55,2015-10-19,185,50,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
01-012,Clinical Site 01,1,36,M,White,Placebo,PLACEBO,Ongoing,2015-04-18,2015-12-21,248,Y,1,2015-06-06,50,2016-04-26,375,N,Y,Visit 2,2,2015-07-31,105,2015-10-19,185,80,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
01-013,Clinical Site 01,1,40,F,White,Treatment A,TRTA,Ongoing,2015-07-15,2016-06-08,330,Y,1,2015-09-11,59,2016-07-08,360,Y,Y,Screening,0,2015-07-15,1,2016-08-03,386,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-013,Clinical Site 01,1,40,F,White,Treatment A,TRTA,Ongoing,2015-07-15,2016-06-08,330,Y,1,2015-09-11,59,2016-07-08,360,Y,Y,Screening,0,2015-07-15,1,2016-08-03,386,62,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-013,Clinical Site 01,1,40,F,White,Treatment A,TRTA,Ongoing,2015-07-15,2016-06-08,330,Y,1,2015-09-11,59,2016-07-08,360,Y,Y,Visit 1,1,2015-09-15,63,2016-08-03,386,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-013,Clinical Site 01,1,40,F,White,Treatment A,TRTA,Ongoing,2015-07-15,2016-06-08,330,Y,1,2015-09-11,59,2016-07-08,360,Y,Y,Visit 1,1,2015-09-15,63,2016-08-03,386,50,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
01-013,Clinical Site 01,1,40,F,White,Treatment A,TRTA,Ongoing,2015-07-15,2016-06-08,330,Y,1,2015-09-11,59,2016-07-08,360,Y,Y,Visit 2,2,2015-11-04,113,2016-08-03,386,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-013,Clinical Site 01,1,40,F,White,Treatment A,TRTA,Ongoing,2015-07-15,2016-06-08,330,Y,1,2015-09-11,59,2016-07-08,360,Y,Y,Visit 2,2,2015-11-04,113,2016-08-03,386,61,RECIST 1.1,Best Overall Response (RECIST 1.1),NE,4,#969696
01-013,Clinical Site 01,1,40,F,White,Treatment A,TRTA,Ongoing,2015-07-15,2016-06-08,330,Y,1,2015-09-11,59,2016-07-08,360,Y,Y,Visit 3,3,2016-01-04,174,2016-08-03,386,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
01-013,Clinical Site 01,1,40,F,White,Treatment A,TRTA,Ongoing,2015-07-15,2016-06-08,330,Y,1,2015-09-11,59,2016-07-08,360,Y,Y,Visit 3,3,2016-01-04,174,2016-08-03,386,56,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-013,Clinical Site 01,1,40,F,White,Treatment A,TRTA,Ongoing,2015-07-15,2016-06-08,330,Y,1,2015-09-11,59,2016-07-08,360,Y,Y,Visit 4,4,2016-02-29,230,2016-08-03,386,63,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-013,Clinical Site 01,1,40,F,White,Treatment A,TRTA,Ongoing,2015-07-15,2016-06-08,330,Y,1,2015-09-11,59,2016-07-08,360,Y,Y,Unscheduled 5.1,5.1,2016-05-02,293,2016-08-03,386,93,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-014,Clinical Site 01,1,37,M,Black,Treatment A,TRTA,Ongoing,2015-07-24,2016-02-14,206,Y,1,2015-09-17,56,2016-07-21,364,Y,Y,Screening,0,2015-07-24,1,2016-04-04,256,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-014,Clinical Site 01,1,37,M,Black,Treatment A,TRTA,Ongoing,2015-07-24,2016-02-14,206,Y,1,2015-09-17,56,2016-07-21,364,Y,Y,Screening,0,2015-07-24,1,2016-04-04,256,61,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-014,Clinical Site 01,1,37,M,Black,Treatment A,TRTA,Ongoing,2015-07-24,2016-02-14,206,Y,1,2015-09-17,56,2016-07-21,364,Y,Y,Visit 1,1,2015-09-23,62,2016-04-04,256,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-014,Clinical Site 01,1,37,M,Black,Treatment A,TRTA,Ongoing,2015-07-24,2016-02-14,206,Y,1,2015-09-17,56,2016-07-21,364,Y,Y,Visit 1,1,2015-09-23,62,2016-04-04,256,43,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
01-014,Clinical Site 01,1,37,M,Black,Treatment A,TRTA,Ongoing,2015-07-24,2016-02-14,206,Y,1,2015-09-17,56,2016-07-21,364,Y,Y,Visit 2,2,2015-11-05,105,2016-04-04,256,68,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-014,Clinical Site 01,1,37,M,Black,Treatment A,TRTA,Ongoing,2015-07-24,2016-02-14,206,Y,1,2015-09-17,56,2016-07-21,364,Y,Y,Visit 3,3,2016-01-12,173,2016-04-04,256,83,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
01-015,Clinical Site 01,1,26,M,Hispanic,Treatment B,TRTB,Ongoing,2015-04-28,2015-11-07,194,Y,1,2015-06-15,49,2016-05-05,374,N,Y,Screening,0,2015-04-28,1,2015-10-03,159,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-015,Clinical Site 01,1,26,M,Hispanic,Treatment B,TRTB,Ongoing,2015-04-28,2015-11-07,194,Y,1,2015-06-15,49,2016-05-05,374,N,Y,Screening,0,2015-04-28,1,2015-10-03,159,62,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-015,Clinical Site 01,1,26,M,Hispanic,Treatment B,TRTB,Ongoing,2015-04-28,2015-11-07,194,Y,1,2015-06-15,49,2016-05-05,374,N,Y,Visit 1,1,2015-06-29,63,2015-10-03,159,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-015,Clinical Site 01,1,26,M,Hispanic,Treatment B,TRTB,Ongoing,2015-04-28,2015-11-07,194,Y,1,2015-06-15,49,2016-05-05,374,N,Y,Visit 1,1,2015-06-29,63,2015-10-03,159,8,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-015,Clinical Site 01,1,26,M,Hispanic,Treatment B,TRTB,Ongoing,2015-04-28,2015-11-07,194,Y,1,2015-06-15,49,2016-05-05,374,N,Y,Unscheduled 1.1,1.1,2015-07-07,71,2015-10-03,159,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-015,Clinical Site 01,1,26,M,Hispanic,Treatment B,TRTB,Ongoing,2015-04-28,2015-11-07,194,Y,1,2015-06-15,49,2016-05-05,374,N,Y,Unscheduled 1.1,1.1,2015-07-07,71,2015-10-03,159,48,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-015,Clinical Site 01,1,26,M,Hispanic,Treatment B,TRTB,Ongoing,2015-04-28,2015-11-07,194,Y,1,2015-06-15,49,2016-05-05,374,N,Y,Visit 2,2,2015-08-24,119,2015-10-03,159,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-015,Clinical Site 01,1,26,M,Hispanic,Treatment B,TRTB,Ongoing,2015-04-28,2015-11-07,194,Y,1,2015-06-15,49,2016-05-05,374,N,Y,Visit 2,2,2015-08-24,119,2015-10-03,159,40,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-016,Clinical Site 01,1,18,M,Black,Treatment A,TRTA,Ongoing,2015-12-21,2016-09-06,261,Y,1,2016-02-09,51,2016-12-28,374,Y,N,Screening,0,2015-12-21,1,2016-09-24,279,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-016,Clinical Site 01,1,18,M,Black,Treatment A,TRTA,Ongoing,2015-12-21,2016-09-06,261,Y,1,2016-02-09,51,2016-12-28,374,Y,N,Screening,0,2015-12-21,1,2016-09-24,279,60,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-016,Clinical Site 01,1,18,M,Black,Treatment A,TRTA,Ongoing,2015-12-21,2016-09-06,261,Y,1,2016-02-09,51,2016-12-28,374,Y,N,Visit 1,1,2016-02-19,61,2016-09-24,279,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-016,Clinical Site 01,1,18,M,Black,Treatment A,TRTA,Ongoing,2015-12-21,2016-09-06,261,Y,1,2016-02-09,51,2016-12-28,374,Y,N,Visit 1,1,2016-02-19,61,2016-09-24,279,44,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-016,Clinical Site 01,1,18,M,Black,Treatment A,TRTA,Ongoing,2015-12-21,2016-09-06,261,Y,1,2016-02-09,51,2016-12-28,374,Y,N,Visit 2,2,2016-04-03,105,2016-09-24,279,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
01-016,Clinical Site 01,1,18,M,Black,Treatment A,TRTA,Ongoing,2015-12-21,2016-09-06,261,Y,1,2016-02-09,51,2016-12-28,374,Y,N,Visit 2,2,2016-04-03,105,2016-09-24,279,67,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-016,Clinical Site 01,1,18,M,Black,Treatment A,TRTA,Ongoing,2015-12-21,2016-09-06,261,Y,1,2016-02-09,51,2016-12-28,374,Y,N,Visit 3,3,2016-06-09,172,2016-09-24,279,56,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
01-016,Clinical Site 01,1,18,M,Black,Treatment A,TRTA,Ongoing,2015-12-21,2016-09-06,261,Y,1,2016-02-09,51,2016-12-28,374,Y,N,Visit 4,4,2016-08-04,228,2016-09-24,279,51,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-017,Clinical Site 01,1,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-02-12,2015-08-05,175,Y,1,2015-04-04,52,2016-02-19,373,Y,Y,Screening,0,2015-02-12,1,2015-08-30,200,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-017,Clinical Site 01,1,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-02-12,2015-08-05,175,Y,1,2015-04-04,52,2016-02-19,373,Y,Y,Screening,0,2015-02-12,1,2015-08-30,200,58,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-017,Clinical Site 01,1,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-02-12,2015-08-05,175,Y,1,2015-04-04,52,2016-02-19,373,Y,Y,Visit 1,1,2015-04-11,59,2015-08-30,200,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-017,Clinical Site 01,1,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-02-12,2015-08-05,175,Y,1,2015-04-04,52,2016-02-19,373,Y,Y,Visit 1,1,2015-04-11,59,2015-08-30,200,50,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-017,Clinical Site 01,1,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-02-12,2015-08-05,175,Y,1,2015-04-04,52,2016-02-19,373,Y,Y,Visit 2,2,2015-05-31,109,2015-08-30,200,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-017,Clinical Site 01,1,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-02-12,2015-08-05,175,Y,1,2015-04-04,52,2016-02-19,373,Y,Y,Visit 2,2,2015-05-31,109,2015-08-30,200,63,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-017,Clinical Site 01,1,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-02-12,2015-08-05,175,Y,1,2015-04-04,52,2016-02-19,373,Y,Y,Visit 3,3,2015-08-02,172,2015-08-30,200,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
01-017,Clinical Site 01,1,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-02-12,2015-08-05,175,Y,1,2015-04-04,52,2016-02-19,373,Y,Y,Visit 3,3,2015-08-02,172,2015-08-30,200,28,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-018,Clinical Site 01,1,29,F,Hispanic,Treatment B,TRTB,Ongoing,2015-02-13,2015-07-01,139,Y,1,2015-04-04,51,2016-02-09,362,Y,N,Screening,0,2015-02-13,1,2015-06-27,135,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-018,Clinical Site 01,1,29,F,Hispanic,Treatment B,TRTB,Ongoing,2015-02-13,2015-07-01,139,Y,1,2015-04-04,51,2016-02-09,362,Y,N,Screening,0,2015-02-13,1,2015-06-27,135,49,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-018,Clinical Site 01,1,29,F,Hispanic,Treatment B,TRTB,Ongoing,2015-02-13,2015-07-01,139,Y,1,2015-04-04,51,2016-02-09,362,Y,N,Visit 1,1,2015-04-03,50,2015-06-27,135,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-018,Clinical Site 01,1,29,F,Hispanic,Treatment B,TRTB,Ongoing,2015-02-13,2015-07-01,139,Y,1,2015-04-04,51,2016-02-09,362,Y,N,Visit 1,1,2015-04-03,50,2015-06-27,135,85,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-019,Clinical Site 01,1,47,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-24,2016-01-31,283,Y,1,2015-06-15,53,2016-04-27,370,Y,Y,Screening,0,2015-04-24,1,2016-01-02,254,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-019,Clinical Site 01,1,47,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-24,2016-01-31,283,Y,1,2015-06-15,53,2016-04-27,370,Y,Y,Screening,0,2015-04-24,1,2016-01-02,254,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-019,Clinical Site 01,1,47,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-24,2016-01-31,283,Y,1,2015-06-15,53,2016-04-27,370,Y,Y,Unscheduled 0.1,0.1,2015-05-02,9,2016-01-02,254,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
01-019,Clinical Site 01,1,47,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-24,2016-01-31,283,Y,1,2015-06-15,53,2016-04-27,370,Y,Y,Unscheduled 0.1,0.1,2015-05-02,9,2016-01-02,254,52,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-019,Clinical Site 01,1,47,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-24,2016-01-31,283,Y,1,2015-06-15,53,2016-04-27,370,Y,Y,Visit 1,1,2015-06-23,61,2016-01-02,254,56,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-019,Clinical Site 01,1,47,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-24,2016-01-31,283,Y,1,2015-06-15,53,2016-04-27,370,Y,Y,Visit 2,2,2015-08-18,117,2016-01-02,254,105,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-019,Clinical Site 01,1,47,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-24,2016-01-31,283,Y,1,2015-06-15,53,2016-04-27,370,Y,Y,Visit 4,4,2015-12-01,222,2016-01-02,254,32,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-021,Clinical Site 01,1,23,F,Black,Treatment A,TRTA,Ongoing,2015-10-04,2015-11-15,43,Y,1,2015-11-21,49,2016-10-01,364,Y,N,Screening,0,2015-10-04,1,2015-12-27,85,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-021,Clinical Site 01,1,23,F,Black,Treatment A,TRTA,Ongoing,2015-10-04,2015-11-15,43,Y,1,2015-11-21,49,2016-10-01,364,Y,N,Screening,0,2015-10-04,1,2015-12-27,85,84,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-022,Clinical Site 01,1,27,F,Black,Treatment A,TRTA,Completed,2015-10-01,2016-09-20,356,Y,1,2015-11-28,59,2016-10-07,373,Y,Y,Screening,0,2015-10-01,1,2016-09-17,353,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-022,Clinical Site 01,1,27,F,Black,Treatment A,TRTA,Completed,2015-10-01,2016-09-20,356,Y,1,2015-11-28,59,2016-10-07,373,Y,Y,Screening,0,2015-10-01,1,2016-09-17,353,56,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-022,Clinical Site 01,1,27,F,Black,Treatment A,TRTA,Completed,2015-10-01,2016-09-20,356,Y,1,2015-11-28,59,2016-10-07,373,Y,Y,Visit 1,1,2015-11-26,57,2016-09-17,353,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
01-022,Clinical Site 01,1,27,F,Black,Treatment A,TRTA,Completed,2015-10-01,2016-09-20,356,Y,1,2015-11-28,59,2016-10-07,373,Y,Y,Visit 1,1,2015-11-26,57,2016-09-17,353,58,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-022,Clinical Site 01,1,27,F,Black,Treatment A,TRTA,Completed,2015-10-01,2016-09-20,356,Y,1,2015-11-28,59,2016-10-07,373,Y,Y,Visit 2,2,2016-01-23,115,2016-09-17,353,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-022,Clinical Site 01,1,27,F,Black,Treatment A,TRTA,Completed,2015-10-01,2016-09-20,356,Y,1,2015-11-28,59,2016-10-07,373,Y,Y,Visit 2,2,2016-01-23,115,2016-09-17,353,48,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
01-022,Clinical Site 01,1,27,F,Black,Treatment A,TRTA,Completed,2015-10-01,2016-09-20,356,Y,1,2015-11-28,59,2016-10-07,373,Y,Y,Visit 3,3,2016-03-11,163,2016-09-17,353,63,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-022,Clinical Site 01,1,27,F,Black,Treatment A,TRTA,Completed,2015-10-01,2016-09-20,356,Y,1,2015-11-28,59,2016-10-07,373,Y,Y,Visit 4,4,2016-05-13,226,2016-09-17,353,56,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-022,Clinical Site 01,1,27,F,Black,Treatment A,TRTA,Completed,2015-10-01,2016-09-20,356,Y,1,2015-11-28,59,2016-10-07,373,Y,Y,Visit 5,5,2016-07-08,282,2016-09-17,353,71,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
01-023,Clinical Site 01,1,48,M,Black,Treatment A,TRTA,Ongoing,2015-03-29,2015-09-03,159,Y,1,2015-05-22,55,2016-03-22,360,Y,Y,Screening,0,2015-03-29,1,2015-07-08,102,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-023,Clinical Site 01,1,48,M,Black,Treatment A,TRTA,Ongoing,2015-03-29,2015-09-03,159,Y,1,2015-05-22,55,2016-03-22,360,Y,Y,Screening,0,2015-03-29,1,2015-07-08,102,69,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-023,Clinical Site 01,1,48,M,Black,Treatment A,TRTA,Ongoing,2015-03-29,2015-09-03,159,Y,1,2015-05-22,55,2016-03-22,360,Y,Y,Unscheduled 1.1,1.1,2015-06-06,70,2015-07-08,102,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-023,Clinical Site 01,1,48,M,Black,Treatment A,TRTA,Ongoing,2015-03-29,2015-09-03,159,Y,1,2015-05-22,55,2016-03-22,360,Y,Y,Unscheduled 1.1,1.1,2015-06-06,70,2015-07-08,102,32,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-024,Clinical Site 01,1,24,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-23,2015-10-28,189,Y,1,2015-06-10,49,2016-04-25,369,N,Y,Screening,0,2015-04-23,1,2015-11-17,209,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-024,Clinical Site 01,1,24,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-23,2015-10-28,189,Y,1,2015-06-10,49,2016-04-25,369,N,Y,Screening,0,2015-04-23,1,2015-11-17,209,48,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-024,Clinical Site 01,1,24,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-23,2015-10-28,189,Y,1,2015-06-10,49,2016-04-25,369,N,Y,Visit 1,1,2015-06-10,49,2015-11-17,209,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-024,Clinical Site 01,1,24,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-23,2015-10-28,189,Y,1,2015-06-10,49,2016-04-25,369,N,Y,Visit 1,1,2015-06-10,49,2015-11-17,209,59,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-024,Clinical Site 01,1,24,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-23,2015-10-28,189,Y,1,2015-06-10,49,2016-04-25,369,N,Y,Visit 2,2,2015-08-08,108,2015-11-17,209,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-024,Clinical Site 01,1,24,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-23,2015-10-28,189,Y,1,2015-06-10,49,2016-04-25,369,N,Y,Visit 2,2,2015-08-08,108,2015-11-17,209,62,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
01-024,Clinical Site 01,1,24,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-04-23,2015-10-28,189,Y,1,2015-06-10,49,2016-04-25,369,N,Y,Visit 3,3,2015-10-09,170,2015-11-17,209,39,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
01-025,Clinical Site 01,1,21,M,White,Placebo,PLACEBO,Ongoing,2015-06-22,2015-09-25,96,Y,1,2015-08-15,55,2016-06-23,368,Y,Y,Screening,0,2015-06-22,1,2015-09-09,80,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-025,Clinical Site 01,1,21,M,White,Placebo,PLACEBO,Ongoing,2015-06-22,2015-09-25,96,Y,1,2015-08-15,55,2016-06-23,368,Y,Y,Screening,0,2015-06-22,1,2015-09-09,80,48,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-025,Clinical Site 01,1,21,M,White,Placebo,PLACEBO,Ongoing,2015-06-22,2015-09-25,96,Y,1,2015-08-15,55,2016-06-23,368,Y,Y,Visit 1,1,2015-08-09,49,2015-09-09,80,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
01-025,Clinical Site 01,1,21,M,White,Placebo,PLACEBO,Ongoing,2015-06-22,2015-09-25,96,Y,1,2015-08-15,55,2016-06-23,368,Y,Y,Visit 1,1,2015-08-09,49,2015-09-09,80,31,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-026,Clinical Site 01,1,25,F,White,Treatment A,TRTA,Completed,2015-02-19,2016-02-28,375,Y,1,2015-04-09,50,2016-02-25,372,Y,Y,Screening,0,2015-02-19,1,2016-04-20,427,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-026,Clinical Site 01,1,25,F,White,Treatment A,TRTA,Completed,2015-02-19,2016-02-28,375,Y,1,2015-04-09,50,2016-02-25,372,Y,Y,Screening,0,2015-02-19,1,2016-04-20,427,59,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-026,Clinical Site 01,1,25,F,White,Treatment A,TRTA,Completed,2015-02-19,2016-02-28,375,Y,1,2015-04-09,50,2016-02-25,372,Y,Y,Visit 1,1,2015-04-19,60,2016-04-20,427,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
01-026,Clinical Site 01,1,25,F,White,Treatment A,TRTA,Completed,2015-02-19,2016-02-28,375,Y,1,2015-04-09,50,2016-02-25,372,Y,Y,Visit 1,1,2015-04-19,60,2016-04-20,427,54,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-026,Clinical Site 01,1,25,F,White,Treatment A,TRTA,Completed,2015-02-19,2016-02-28,375,Y,1,2015-04-09,50,2016-02-25,372,Y,Y,Visit 2,2,2015-06-12,114,2016-04-20,427,51,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-026,Clinical Site 01,1,25,F,White,Treatment A,TRTA,Completed,2015-02-19,2016-02-28,375,Y,1,2015-04-09,50,2016-02-25,372,Y,Y,Visit 3,3,2015-08-02,165,2016-04-20,427,64,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-026,Clinical Site 01,1,25,F,White,Treatment A,TRTA,Completed,2015-02-19,2016-02-28,375,Y,1,2015-04-09,50,2016-02-25,372,Y,Y,Visit 4,4,2015-10-05,229,2016-04-20,427,8,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-026,Clinical Site 01,1,25,F,White,Treatment A,TRTA,Completed,2015-02-19,2016-02-28,375,Y,1,2015-04-09,50,2016-02-25,372,Y,Y,Unscheduled 4.1,4.1,2015-10-13,237,2016-04-20,427,37,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-026,Clinical Site 01,1,25,F,White,Treatment A,TRTA,Completed,2015-02-19,2016-02-28,375,Y,1,2015-04-09,50,2016-02-25,372,Y,Y,Visit 5,5,2015-11-19,274,2016-04-20,427,58,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-026,Clinical Site 01,1,25,F,White,Treatment A,TRTA,Completed,2015-02-19,2016-02-28,375,Y,1,2015-04-09,50,2016-02-25,372,Y,Y,Visit 6,6,2016-01-16,332,2016-04-20,427,34,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-026,Clinical Site 01,1,25,F,White,Treatment A,TRTA,Completed,2015-02-19,2016-02-28,375,Y,1,2015-04-09,50,2016-02-25,372,Y,Y,End of Study,7,2016-02-19,366,2016-04-20,427,61,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
01-027,Clinical Site 01,1,40,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-06-01,2015-10-24,146,Y,1,2015-07-26,56,2016-05-25,360,Y,Y,Screening,0,2015-06-01,1,2015-11-03,156,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-027,Clinical Site 01,1,40,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-06-01,2015-10-24,146,Y,1,2015-07-26,56,2016-05-25,360,Y,Y,Screening,0,2015-06-01,1,2015-11-03,156,53,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-027,Clinical Site 01,1,40,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-06-01,2015-10-24,146,Y,1,2015-07-26,56,2016-05-25,360,Y,Y,Visit 1,1,2015-07-24,54,2015-11-03,156,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-027,Clinical Site 01,1,40,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-06-01,2015-10-24,146,Y,1,2015-07-26,56,2016-05-25,360,Y,Y,Visit 1,1,2015-07-24,54,2015-11-03,156,102,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Screening,0,2015-11-12,1,2017-01-29,445,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Screening,0,2015-11-12,1,2017-01-29,445,60,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Visit 1,1,2016-01-11,61,2017-01-29,445,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Visit 1,1,2016-01-11,61,2017-01-29,445,8,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Unscheduled 1.1,1.1,2016-01-19,69,2017-01-29,445,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Unscheduled 1.1,1.1,2016-01-19,69,2017-01-29,445,41,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Visit 2,2,2016-02-29,110,2017-01-29,445,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Visit 2,2,2016-02-29,110,2017-01-29,445,61,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Visit 3,3,2016-04-30,171,2017-01-29,445,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Visit 3,3,2016-04-30,171,2017-01-29,445,102,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Visit 5,5,2016-08-10,273,2017-01-29,445,70,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,Visit 6,6,2016-10-19,343,2017-01-29,445,25,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-028,Clinical Site 01,1,21,F,Hispanic,Treatment B,TRTB,Completed,2015-11-12,2016-11-04,359,Y,1,2016-01-02,52,2016-11-04,359,Y,Y,End of Study,7,2016-11-13,368,2017-01-29,445,77,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-029,Clinical Site 01,1,50,M,Black,Placebo,PLACEBO,Ongoing,2015-06-10,2016-05-23,349,Y,1,2015-08-06,58,2016-06-16,373,Y,Y,Screening,0,2015-06-10,1,2016-06-29,386,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
01-029,Clinical Site 01,1,50,M,Black,Placebo,PLACEBO,Ongoing,2015-06-10,2016-05-23,349,Y,1,2015-08-06,58,2016-06-16,373,Y,Y,Screening,0,2015-06-10,1,2016-06-29,386,48,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
01-029,Clinical Site 01,1,50,M,Black,Placebo,PLACEBO,Ongoing,2015-06-10,2016-05-23,349,Y,1,2015-08-06,58,2016-06-16,373,Y,Y,Visit 1,1,2015-07-28,49,2016-06-29,386,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-029,Clinical Site 01,1,50,M,Black,Placebo,PLACEBO,Ongoing,2015-06-10,2016-05-23,349,Y,1,2015-08-06,58,2016-06-16,373,Y,Y,Visit 1,1,2015-07-28,49,2016-06-29,386,66,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
01-029,Clinical Site 01,1,50,M,Black,Placebo,PLACEBO,Ongoing,2015-06-10,2016-05-23,349,Y,1,2015-08-06,58,2016-06-16,373,Y,Y,Visit 2,2,2015-10-02,115,2016-06-29,386,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-029,Clinical Site 01,1,50,M,Black,Placebo,PLACEBO,Ongoing,2015-06-10,2016-05-23,349,Y,1,2015-08-06,58,2016-06-16,373,Y,Y,Visit 2,2,2015-10-02,115,2016-06-29,386,52,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
01-029,Clinical Site 01,1,50,M,Black,Placebo,PLACEBO,Ongoing,2015-06-10,2016-05-23,349,Y,1,2015-08-06,58,2016-06-16,373,Y,Y,Visit 3,3,2015-11-23,167,2016-06-29,386,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
01-029,Clinical Site 01,1,50,M,Black,Placebo,PLACEBO,Ongoing,2015-06-10,2016-05-23,349,Y,1,2015-08-06,58,2016-06-16,373,Y,Y,Visit 3,3,2015-11-23,167,2016-06-29,386,59,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
01-029,Clinical Site 01,1,50,M,Black,Placebo,PLACEBO,Ongoing,2015-06-10,2016-05-23,349,Y,1,2015-08-06,58,2016-06-16,373,Y,Y,Visit 4,4,2016-01-21,226,2016-06-29,386,60,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
01-029,Clinical Site 01,1,50,M,Black,Placebo,PLACEBO,Ongoing,2015-06-10,2016-05-23,349,Y,1,2015-08-06,58,2016-06-16,373,Y,Y,Visit 5,5,2016-03-21,286,2016-06-29,386,100,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-002,Clinical Site 02,2,42,F,White,Treatment B,TRTB,Ongoing,2015-03-16,2015-07-18,125,Y,1,2015-05-16,62,2016-03-22,373,Y,Y,Screening,0,2015-03-16,1,2015-05-03,49,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-002,Clinical Site 02,2,42,F,White,Treatment B,TRTB,Ongoing,2015-03-16,2015-07-18,125,Y,1,2015-05-16,62,2016-03-22,373,Y,Y,Screening,0,2015-03-16,1,2015-05-03,49,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-002,Clinical Site 02,2,42,F,White,Treatment B,TRTB,Ongoing,2015-03-16,2015-07-18,125,Y,1,2015-05-16,62,2016-03-22,373,Y,Y,Unscheduled 0.1,0.1,2015-03-24,9,2015-05-03,49,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-002,Clinical Site 02,2,42,F,White,Treatment B,TRTB,Ongoing,2015-03-16,2015-07-18,125,Y,1,2015-05-16,62,2016-03-22,373,Y,Y,Unscheduled 0.1,0.1,2015-03-24,9,2015-05-03,49,40,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
02-003,Clinical Site 02,2,27,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-27,2015-12-14,232,Y,1,2015-06-26,61,2016-05-05,375,Y,Y,Screening,0,2015-04-27,1,2016-01-09,258,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-003,Clinical Site 02,2,27,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-27,2015-12-14,232,Y,1,2015-06-26,61,2016-05-05,375,Y,Y,Screening,0,2015-04-27,1,2016-01-09,258,58,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-003,Clinical Site 02,2,27,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-27,2015-12-14,232,Y,1,2015-06-26,61,2016-05-05,375,Y,Y,Visit 1,1,2015-06-24,59,2016-01-09,258,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-003,Clinical Site 02,2,27,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-27,2015-12-14,232,Y,1,2015-06-26,61,2016-05-05,375,Y,Y,Visit 1,1,2015-06-24,59,2016-01-09,258,50,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-003,Clinical Site 02,2,27,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-27,2015-12-14,232,Y,1,2015-06-26,61,2016-05-05,375,Y,Y,Visit 2,2,2015-08-13,109,2016-01-09,258,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-003,Clinical Site 02,2,27,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-27,2015-12-14,232,Y,1,2015-06-26,61,2016-05-05,375,Y,Y,Visit 2,2,2015-08-13,109,2016-01-09,258,54,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-003,Clinical Site 02,2,27,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-27,2015-12-14,232,Y,1,2015-06-26,61,2016-05-05,375,Y,Y,Visit 3,3,2015-10-06,163,2016-01-09,258,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-003,Clinical Site 02,2,27,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-27,2015-12-14,232,Y,1,2015-06-26,61,2016-05-05,375,Y,Y,Visit 3,3,2015-10-06,163,2016-01-09,258,95,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-004,Clinical Site 02,2,21,F,White,Placebo,PLACEBO,Ongoing,2015-09-30,2015-10-21,22,Y,1,2015-11-20,52,2016-10-05,372,Y,Y,Screening,0,2015-09-30,1,2016-01-04,97,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-004,Clinical Site 02,2,21,F,White,Placebo,PLACEBO,Ongoing,2015-09-30,2015-10-21,22,Y,1,2015-11-20,52,2016-10-05,372,Y,Y,Screening,0,2015-09-30,1,2016-01-04,97,96,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-008,Clinical Site 02,2,21,F,Other/Mixed,Treatment B,TRTB,Completed,2015-08-17,2016-08-23,373,Y,1,2015-10-12,57,2016-08-14,364,Y,Y,Screening,0,2015-08-17,1,2016-02-05,173,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-008,Clinical Site 02,2,21,F,Other/Mixed,Treatment B,TRTB,Completed,2015-08-17,2016-08-23,373,Y,1,2015-10-12,57,2016-08-14,364,Y,Y,Screening,0,2015-08-17,1,2016-02-05,173,50,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-008,Clinical Site 02,2,21,F,Other/Mixed,Treatment B,TRTB,Completed,2015-08-17,2016-08-23,373,Y,1,2015-10-12,57,2016-08-14,364,Y,Y,Visit 1,1,2015-10-06,51,2016-02-05,173,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
02-008,Clinical Site 02,2,21,F,Other/Mixed,Treatment B,TRTB,Completed,2015-08-17,2016-08-23,373,Y,1,2015-10-12,57,2016-08-14,364,Y,Y,Visit 1,1,2015-10-06,51,2016-02-05,173,65,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-008,Clinical Site 02,2,21,F,Other/Mixed,Treatment B,TRTB,Completed,2015-08-17,2016-08-23,373,Y,1,2015-10-12,57,2016-08-14,364,Y,Y,Visit 2,2,2015-12-10,116,2016-02-05,173,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-008,Clinical Site 02,2,21,F,Other/Mixed,Treatment B,TRTB,Completed,2015-08-17,2016-08-23,373,Y,1,2015-10-12,57,2016-08-14,364,Y,Y,Visit 2,2,2015-12-10,116,2016-02-05,173,57,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-009,Clinical Site 02,2,27,F,Black,Treatment B,TRTB,Ongoing,2015-12-13,2016-07-30,231,Y,1,2016-02-04,54,2016-12-09,363,Y,Y,Screening,0,2015-12-13,1,2016-10-20,313,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-009,Clinical Site 02,2,27,F,Black,Treatment B,TRTB,Ongoing,2015-12-13,2016-07-30,231,Y,1,2016-02-04,54,2016-12-09,363,Y,Y,Screening,0,2015-12-13,1,2016-10-20,313,52,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-009,Clinical Site 02,2,27,F,Black,Treatment B,TRTB,Ongoing,2015-12-13,2016-07-30,231,Y,1,2016-02-04,54,2016-12-09,363,Y,Y,Visit 1,1,2016-02-03,53,2016-10-20,313,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-009,Clinical Site 02,2,27,F,Black,Treatment B,TRTB,Ongoing,2015-12-13,2016-07-30,231,Y,1,2016-02-04,54,2016-12-09,363,Y,Y,Visit 1,1,2016-02-03,53,2016-10-20,313,114,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-009,Clinical Site 02,2,27,F,Black,Treatment B,TRTB,Ongoing,2015-12-13,2016-07-30,231,Y,1,2016-02-04,54,2016-12-09,363,Y,Y,Visit 3,3,2016-05-27,167,2016-10-20,313,54,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-009,Clinical Site 02,2,27,F,Black,Treatment B,TRTB,Ongoing,2015-12-13,2016-07-30,231,Y,1,2016-02-04,54,2016-12-09,363,Y,Y,Visit 4,4,2016-07-20,221,2016-10-20,313,92,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Screening,0,2015-07-26,1,2016-08-09,381,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Screening,0,2015-07-26,1,2016-08-09,381,50,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Visit 1,1,2015-09-14,51,2016-08-09,381,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Visit 1,1,2015-09-14,51,2016-08-09,381,55,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Visit 2,2,2015-11-08,106,2016-08-09,381,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Visit 2,2,2015-11-08,106,2016-08-09,381,59,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Visit 3,3,2016-01-06,165,2016-08-09,381,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Visit 3,3,2016-01-06,165,2016-08-09,381,55,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Visit 4,4,2016-03-01,220,2016-08-09,381,66,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Visit 5,5,2016-05-06,286,2016-08-09,381,8,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Unscheduled 5.1,5.1,2016-05-14,294,2016-08-09,381,47,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Visit 6,6,2016-06-30,341,2016-08-09,381,8,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-010,Clinical Site 02,2,36,F,White,Treatment B,TRTB,Completed,2015-07-26,2016-07-18,359,Y,1,2015-09-13,50,2016-07-26,367,Y,Y,Unscheduled 6.1,6.1,2016-07-08,349,2016-08-09,381,32,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-011,Clinical Site 02,2,40,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-10-08,2015-10-13,6,Y,1,2015-11-27,51,2016-10-14,373,Y,N,Screening,0,2015-10-08,1,2015-11-24,48,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-011,Clinical Site 02,2,40,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-10-08,2015-10-13,6,Y,1,2015-11-27,51,2016-10-14,373,Y,N,Screening,0,2015-10-08,1,2015-11-24,48,47,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Screening,0,2015-09-30,1,2016-08-10,316,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Screening,0,2015-09-30,1,2016-08-10,316,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Unscheduled 0.1,0.1,2015-10-08,9,2016-08-10,316,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Unscheduled 0.1,0.1,2015-10-08,9,2016-08-10,316,48,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Visit 1,1,2015-11-25,57,2016-08-10,316,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Visit 1,1,2015-11-25,57,2016-08-10,316,8,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Unscheduled 1.1,1.1,2015-12-03,65,2016-08-10,316,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Unscheduled 1.1,1.1,2015-12-03,65,2016-08-10,316,50,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Visit 2,2,2016-01-22,115,2016-08-10,316,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Visit 2,2,2016-01-22,115,2016-08-10,316,48,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Visit 3,3,2016-03-10,163,2016-08-10,316,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Visit 3,3,2016-03-10,163,2016-08-10,316,65,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Visit 4,4,2016-05-14,228,2016-08-10,316,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-012,Clinical Site 02,2,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-09-30,2016-07-25,300,Y,1,2015-11-26,58,2016-09-18,355,Y,Y,Visit 4,4,2016-05-14,228,2016-08-10,316,88,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-013,Clinical Site 02,2,32,M,White,Treatment B,TRTB,Completed,2015-12-29,2016-12-20,358,Y,1,2016-02-24,58,2016-12-18,356,Y,Y,Screening,0,2015-12-29,1,2017-01-12,381,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-013,Clinical Site 02,2,32,M,White,Treatment B,TRTB,Completed,2015-12-29,2016-12-20,358,Y,1,2016-02-24,58,2016-12-18,356,Y,Y,Screening,0,2015-12-29,1,2017-01-12,381,51,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-013,Clinical Site 02,2,32,M,White,Treatment B,TRTB,Completed,2015-12-29,2016-12-20,358,Y,1,2016-02-24,58,2016-12-18,356,Y,Y,Visit 1,1,2016-02-18,52,2017-01-12,381,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
02-013,Clinical Site 02,2,32,M,White,Treatment B,TRTB,Completed,2015-12-29,2016-12-20,358,Y,1,2016-02-24,58,2016-12-18,356,Y,Y,Visit 1,1,2016-02-18,52,2017-01-12,381,67,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-013,Clinical Site 02,2,32,M,White,Treatment B,TRTB,Completed,2015-12-29,2016-12-20,358,Y,1,2016-02-24,58,2016-12-18,356,Y,Y,Visit 2,2,2016-04-25,119,2017-01-12,381,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-013,Clinical Site 02,2,32,M,White,Treatment B,TRTB,Completed,2015-12-29,2016-12-20,358,Y,1,2016-02-24,58,2016-12-18,356,Y,Y,Visit 2,2,2016-04-25,119,2017-01-12,381,53,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-013,Clinical Site 02,2,32,M,White,Treatment B,TRTB,Completed,2015-12-29,2016-12-20,358,Y,1,2016-02-24,58,2016-12-18,356,Y,Y,Visit 3,3,2016-06-17,172,2017-01-12,381,114,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-013,Clinical Site 02,2,32,M,White,Treatment B,TRTB,Completed,2015-12-29,2016-12-20,358,Y,1,2016-02-24,58,2016-12-18,356,Y,Y,Visit 5,5,2016-10-09,286,2017-01-12,381,95,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-014,Clinical Site 02,2,19,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-13,2015-09-19,160,Y,1,2015-06-05,54,2016-04-16,370,Y,N,Screening,0,2015-04-13,1,2015-10-03,174,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-014,Clinical Site 02,2,19,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-13,2015-09-19,160,Y,1,2015-06-05,54,2016-04-16,370,Y,N,Screening,0,2015-04-13,1,2015-10-03,174,58,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-014,Clinical Site 02,2,19,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-13,2015-09-19,160,Y,1,2015-06-05,54,2016-04-16,370,Y,N,Visit 1,1,2015-06-10,59,2015-10-03,174,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-014,Clinical Site 02,2,19,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-13,2015-09-19,160,Y,1,2015-06-05,54,2016-04-16,370,Y,N,Visit 1,1,2015-06-10,59,2015-10-03,174,8,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-014,Clinical Site 02,2,19,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-13,2015-09-19,160,Y,1,2015-06-05,54,2016-04-16,370,Y,N,Unscheduled 1.1,1.1,2015-06-18,67,2015-10-03,174,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-014,Clinical Site 02,2,19,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-13,2015-09-19,160,Y,1,2015-06-05,54,2016-04-16,370,Y,N,Unscheduled 1.1,1.1,2015-06-18,67,2015-10-03,174,40,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-014,Clinical Site 02,2,19,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-13,2015-09-19,160,Y,1,2015-06-05,54,2016-04-16,370,Y,N,Visit 2,2,2015-07-28,107,2015-10-03,174,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-014,Clinical Site 02,2,19,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-13,2015-09-19,160,Y,1,2015-06-05,54,2016-04-16,370,Y,N,Visit 2,2,2015-07-28,107,2015-10-03,174,67,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-015,Clinical Site 02,2,29,M,White,Placebo,PLACEBO,Ongoing,2015-02-24,2015-05-14,80,Y,1,2015-04-17,53,2016-02-20,362,Y,Y,Screening,0,2015-02-24,1,2015-05-05,71,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-015,Clinical Site 02,2,29,M,White,Placebo,PLACEBO,Ongoing,2015-02-24,2015-05-14,80,Y,1,2015-04-17,53,2016-02-20,362,Y,Y,Screening,0,2015-02-24,1,2015-05-05,71,70,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-017,Clinical Site 02,2,33,M,White,Placebo,PLACEBO,Completed,2015-04-06,2016-03-27,357,Y,1,2015-06-03,59,2016-03-25,355,Y,Y,Screening,0,2015-04-06,1,2015-09-28,176,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-017,Clinical Site 02,2,33,M,White,Placebo,PLACEBO,Completed,2015-04-06,2016-03-27,357,Y,1,2015-06-03,59,2016-03-25,355,Y,Y,Screening,0,2015-04-06,1,2015-09-28,176,61,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-017,Clinical Site 02,2,33,M,White,Placebo,PLACEBO,Completed,2015-04-06,2016-03-27,357,Y,1,2015-06-03,59,2016-03-25,355,Y,Y,Visit 1,1,2015-06-06,62,2015-09-28,176,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-017,Clinical Site 02,2,33,M,White,Placebo,PLACEBO,Completed,2015-04-06,2016-03-27,357,Y,1,2015-06-03,59,2016-03-25,355,Y,Y,Visit 1,1,2015-06-06,62,2015-09-28,176,8,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-017,Clinical Site 02,2,33,M,White,Placebo,PLACEBO,Completed,2015-04-06,2016-03-27,357,Y,1,2015-06-03,59,2016-03-25,355,Y,Y,Unscheduled 1.1,1.1,2015-06-14,70,2015-09-28,176,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-017,Clinical Site 02,2,33,M,White,Placebo,PLACEBO,Completed,2015-04-06,2016-03-27,357,Y,1,2015-06-03,59,2016-03-25,355,Y,Y,Unscheduled 1.1,1.1,2015-06-14,70,2015-09-28,176,106,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-018,Clinical Site 02,2,19,F,White,Placebo,PLACEBO,Completed,2015-11-23,2016-11-21,365,Y,1,2016-01-16,55,2016-11-13,357,Y,Y,Screening,0,2015-11-23,1,2017-01-14,419,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-018,Clinical Site 02,2,19,F,White,Placebo,PLACEBO,Completed,2015-11-23,2016-11-21,365,Y,1,2016-01-16,55,2016-11-13,357,Y,Y,Screening,0,2015-11-23,1,2017-01-14,419,51,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-018,Clinical Site 02,2,19,F,White,Placebo,PLACEBO,Completed,2015-11-23,2016-11-21,365,Y,1,2016-01-16,55,2016-11-13,357,Y,Y,Visit 1,1,2016-01-13,52,2017-01-14,419,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-018,Clinical Site 02,2,19,F,White,Placebo,PLACEBO,Completed,2015-11-23,2016-11-21,365,Y,1,2016-01-16,55,2016-11-13,357,Y,Y,Visit 1,1,2016-01-13,52,2017-01-14,419,115,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-018,Clinical Site 02,2,19,F,White,Placebo,PLACEBO,Completed,2015-11-23,2016-11-21,365,Y,1,2016-01-16,55,2016-11-13,357,Y,Y,Visit 3,3,2016-05-07,167,2017-01-14,419,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-018,Clinical Site 02,2,19,F,White,Placebo,PLACEBO,Completed,2015-11-23,2016-11-21,365,Y,1,2016-01-16,55,2016-11-13,357,Y,Y,Visit 3,3,2016-05-07,167,2017-01-14,419,51,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
02-018,Clinical Site 02,2,19,F,White,Placebo,PLACEBO,Completed,2015-11-23,2016-11-21,365,Y,1,2016-01-16,55,2016-11-13,357,Y,Y,Visit 4,4,2016-06-27,218,2017-01-14,419,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-018,Clinical Site 02,2,19,F,White,Placebo,PLACEBO,Completed,2015-11-23,2016-11-21,365,Y,1,2016-01-16,55,2016-11-13,357,Y,Y,Visit 4,4,2016-06-27,218,2017-01-14,419,67,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-018,Clinical Site 02,2,19,F,White,Placebo,PLACEBO,Completed,2015-11-23,2016-11-21,365,Y,1,2016-01-16,55,2016-11-13,357,Y,Y,Visit 5,5,2016-09-02,285,2017-01-14,419,47,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-018,Clinical Site 02,2,19,F,White,Placebo,PLACEBO,Completed,2015-11-23,2016-11-21,365,Y,1,2016-01-16,55,2016-11-13,357,Y,Y,Visit 6,6,2016-10-19,332,2017-01-14,419,87,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-019,Clinical Site 02,2,49,F,Black,Placebo,PLACEBO,Ongoing,2015-02-16,2015-09-27,224,Y,1,2015-04-06,50,2016-02-13,363,N,Y,Screening,0,2015-02-16,1,2015-11-16,274,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-019,Clinical Site 02,2,49,F,Black,Placebo,PLACEBO,Ongoing,2015-02-16,2015-09-27,224,Y,1,2015-04-06,50,2016-02-13,363,N,Y,Screening,0,2015-02-16,1,2015-11-16,274,63,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-019,Clinical Site 02,2,49,F,Black,Placebo,PLACEBO,Ongoing,2015-02-16,2015-09-27,224,Y,1,2015-04-06,50,2016-02-13,363,N,Y,Unscheduled 1.1,1.1,2015-04-20,64,2015-11-16,274,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-019,Clinical Site 02,2,49,F,Black,Placebo,PLACEBO,Ongoing,2015-02-16,2015-09-27,224,Y,1,2015-04-06,50,2016-02-13,363,N,Y,Unscheduled 1.1,1.1,2015-04-20,64,2015-11-16,274,44,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-019,Clinical Site 02,2,49,F,Black,Placebo,PLACEBO,Ongoing,2015-02-16,2015-09-27,224,Y,1,2015-04-06,50,2016-02-13,363,N,Y,Visit 2,2,2015-06-03,108,2015-11-16,274,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-019,Clinical Site 02,2,49,F,Black,Placebo,PLACEBO,Ongoing,2015-02-16,2015-09-27,224,Y,1,2015-04-06,50,2016-02-13,363,N,Y,Visit 2,2,2015-06-03,108,2015-11-16,274,53,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-019,Clinical Site 02,2,49,F,Black,Placebo,PLACEBO,Ongoing,2015-02-16,2015-09-27,224,Y,1,2015-04-06,50,2016-02-13,363,N,Y,Visit 3,3,2015-07-26,161,2015-11-16,274,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
02-019,Clinical Site 02,2,49,F,Black,Placebo,PLACEBO,Ongoing,2015-02-16,2015-09-27,224,Y,1,2015-04-06,50,2016-02-13,363,N,Y,Visit 3,3,2015-07-26,161,2015-11-16,274,62,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-019,Clinical Site 02,2,49,F,Black,Placebo,PLACEBO,Ongoing,2015-02-16,2015-09-27,224,Y,1,2015-04-06,50,2016-02-13,363,N,Y,Visit 4,4,2015-09-26,223,2015-11-16,274,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-019,Clinical Site 02,2,49,F,Black,Placebo,PLACEBO,Ongoing,2015-02-16,2015-09-27,224,Y,1,2015-04-06,50,2016-02-13,363,N,Y,Visit 4,4,2015-09-26,223,2015-11-16,274,51,RECIST 1.1,Best Overall Response (RECIST 1.1),NE,4,#969696
02-021,Clinical Site 02,2,53,F,Black,Treatment B,TRTB,Ongoing,2015-10-01,2016-09-03,339,Y,1,2015-11-22,53,2016-10-04,370,Y,Y,Screening,0,2015-10-01,1,2016-11-15,412,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-021,Clinical Site 02,2,53,F,Black,Treatment B,TRTB,Ongoing,2015-10-01,2016-09-03,339,Y,1,2015-11-22,53,2016-10-04,370,Y,Y,Screening,0,2015-10-01,1,2016-11-15,412,59,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-021,Clinical Site 02,2,53,F,Black,Treatment B,TRTB,Ongoing,2015-10-01,2016-09-03,339,Y,1,2015-11-22,53,2016-10-04,370,Y,Y,Visit 1,1,2015-11-29,60,2016-11-15,412,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-021,Clinical Site 02,2,53,F,Black,Treatment B,TRTB,Ongoing,2015-10-01,2016-09-03,339,Y,1,2015-11-22,53,2016-10-04,370,Y,Y,Visit 1,1,2015-11-29,60,2016-11-15,412,58,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-021,Clinical Site 02,2,53,F,Black,Treatment B,TRTB,Ongoing,2015-10-01,2016-09-03,339,Y,1,2015-11-22,53,2016-10-04,370,Y,Y,Visit 2,2,2016-01-26,118,2016-11-15,412,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
02-021,Clinical Site 02,2,53,F,Black,Treatment B,TRTB,Ongoing,2015-10-01,2016-09-03,339,Y,1,2015-11-22,53,2016-10-04,370,Y,Y,Visit 2,2,2016-01-26,118,2016-11-15,412,53,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-021,Clinical Site 02,2,53,F,Black,Treatment B,TRTB,Ongoing,2015-10-01,2016-09-03,339,Y,1,2015-11-22,53,2016-10-04,370,Y,Y,Visit 3,3,2016-03-19,171,2016-11-15,412,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-021,Clinical Site 02,2,53,F,Black,Treatment B,TRTB,Ongoing,2015-10-01,2016-09-03,339,Y,1,2015-11-22,53,2016-10-04,370,Y,Y,Visit 3,3,2016-03-19,171,2016-11-15,412,52,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-021,Clinical Site 02,2,53,F,Black,Treatment B,TRTB,Ongoing,2015-10-01,2016-09-03,339,Y,1,2015-11-22,53,2016-10-04,370,Y,Y,Visit 4,4,2016-05-10,223,2016-11-15,412,60,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-021,Clinical Site 02,2,53,F,Black,Treatment B,TRTB,Ongoing,2015-10-01,2016-09-03,339,Y,1,2015-11-22,53,2016-10-04,370,Y,Y,Visit 5,5,2016-07-09,283,2016-11-15,412,46,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-021,Clinical Site 02,2,53,F,Black,Treatment B,TRTB,Ongoing,2015-10-01,2016-09-03,339,Y,1,2015-11-22,53,2016-10-04,370,Y,Y,Visit 6,6,2016-08-24,329,2016-11-15,412,83,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
02-022,Clinical Site 02,2,30,M,White,Treatment B,TRTB,Ongoing,2015-12-27,2016-03-02,67,Y,1,2016-02-15,51,2016-12-16,356,Y,Y,Screening,0,2015-12-27,1,2016-01-28,33,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-022,Clinical Site 02,2,30,M,White,Treatment B,TRTB,Ongoing,2015-12-27,2016-03-02,67,Y,1,2016-02-15,51,2016-12-16,356,Y,Y,Screening,0,2015-12-27,1,2016-01-28,33,32,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-023,Clinical Site 02,2,45,F,Black,Treatment A,TRTA,Completed,2015-12-06,2016-12-09,370,Y,1,2016-02-03,60,2016-11-26,357,Y,Y,Screening,0,2015-12-06,1,2016-12-18,379,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-023,Clinical Site 02,2,45,F,Black,Treatment A,TRTA,Completed,2015-12-06,2016-12-09,370,Y,1,2016-02-03,60,2016-11-26,357,Y,Y,Screening,0,2015-12-06,1,2016-12-18,379,54,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-023,Clinical Site 02,2,45,F,Black,Treatment A,TRTA,Completed,2015-12-06,2016-12-09,370,Y,1,2016-02-03,60,2016-11-26,357,Y,Y,Visit 1,1,2016-01-29,55,2016-12-18,379,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-023,Clinical Site 02,2,45,F,Black,Treatment A,TRTA,Completed,2015-12-06,2016-12-09,370,Y,1,2016-02-03,60,2016-11-26,357,Y,Y,Visit 1,1,2016-01-29,55,2016-12-18,379,60,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-023,Clinical Site 02,2,45,F,Black,Treatment A,TRTA,Completed,2015-12-06,2016-12-09,370,Y,1,2016-02-03,60,2016-11-26,357,Y,Y,Visit 2,2,2016-03-29,115,2016-12-18,379,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-023,Clinical Site 02,2,45,F,Black,Treatment A,TRTA,Completed,2015-12-06,2016-12-09,370,Y,1,2016-02-03,60,2016-11-26,357,Y,Y,Visit 2,2,2016-03-29,115,2016-12-18,379,53,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
02-023,Clinical Site 02,2,45,F,Black,Treatment A,TRTA,Completed,2015-12-06,2016-12-09,370,Y,1,2016-02-03,60,2016-11-26,357,Y,Y,Visit 3,3,2016-05-21,168,2016-12-18,379,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-023,Clinical Site 02,2,45,F,Black,Treatment A,TRTA,Completed,2015-12-06,2016-12-09,370,Y,1,2016-02-03,60,2016-11-26,357,Y,Y,Visit 3,3,2016-05-21,168,2016-12-18,379,63,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
02-023,Clinical Site 02,2,45,F,Black,Treatment A,TRTA,Completed,2015-12-06,2016-12-09,370,Y,1,2016-02-03,60,2016-11-26,357,Y,Y,Visit 4,4,2016-07-23,231,2016-12-18,379,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-023,Clinical Site 02,2,45,F,Black,Treatment A,TRTA,Completed,2015-12-06,2016-12-09,370,Y,1,2016-02-03,60,2016-11-26,357,Y,Y,Visit 4,4,2016-07-23,231,2016-12-18,379,53,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
02-023,Clinical Site 02,2,45,F,Black,Treatment A,TRTA,Completed,2015-12-06,2016-12-09,370,Y,1,2016-02-03,60,2016-11-26,357,Y,Y,Visit 5,5,2016-09-14,284,2016-12-18,379,95,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-024,Clinical Site 02,2,45,M,White,Treatment A,TRTA,Ongoing,2015-02-28,2015-07-20,143,Y,1,2015-04-27,59,2016-02-27,365,Y,Y,Screening,0,2015-02-28,1,2015-06-18,111,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-024,Clinical Site 02,2,45,M,White,Treatment A,TRTA,Ongoing,2015-02-28,2015-07-20,143,Y,1,2015-04-27,59,2016-02-27,365,Y,Y,Screening,0,2015-02-28,1,2015-06-18,111,110,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-026,Clinical Site 02,2,27,F,Black,Placebo,PLACEBO,Completed,2015-04-03,2016-04-05,369,Y,1,2015-05-21,49,2016-03-25,358,Y,Y,Screening,0,2015-04-03,1,2016-06-02,427,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-026,Clinical Site 02,2,27,F,Black,Placebo,PLACEBO,Completed,2015-04-03,2016-04-05,369,Y,1,2015-05-21,49,2016-03-25,358,Y,Y,Screening,0,2015-04-03,1,2016-06-02,427,170,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-026,Clinical Site 02,2,27,F,Black,Placebo,PLACEBO,Completed,2015-04-03,2016-04-05,369,Y,1,2015-05-21,49,2016-03-25,358,Y,Y,Visit 3,3,2015-09-20,171,2016-06-02,427,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-026,Clinical Site 02,2,27,F,Black,Placebo,PLACEBO,Completed,2015-04-03,2016-04-05,369,Y,1,2015-05-21,49,2016-03-25,358,Y,Y,Visit 3,3,2015-09-20,171,2016-06-02,427,8,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-026,Clinical Site 02,2,27,F,Black,Placebo,PLACEBO,Completed,2015-04-03,2016-04-05,369,Y,1,2015-05-21,49,2016-03-25,358,Y,Y,Unscheduled 3.1,3.1,2015-09-28,179,2016-06-02,427,155,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-026,Clinical Site 02,2,27,F,Black,Placebo,PLACEBO,Completed,2015-04-03,2016-04-05,369,Y,1,2015-05-21,49,2016-03-25,358,Y,Y,Visit 6,6,2016-03-01,334,2016-06-02,427,93,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-027,Clinical Site 02,2,36,F,Hispanic,Treatment B,TRTB,Completed,2015-03-08,2016-03-02,361,Y,1,2015-04-25,49,2016-03-02,361,Y,Y,Screening,0,2015-03-08,1,2016-05-27,447,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-027,Clinical Site 02,2,36,F,Hispanic,Treatment B,TRTB,Completed,2015-03-08,2016-03-02,361,Y,1,2015-04-25,49,2016-03-02,361,Y,Y,Screening,0,2015-03-08,1,2016-05-27,447,61,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-027,Clinical Site 02,2,36,F,Hispanic,Treatment B,TRTB,Completed,2015-03-08,2016-03-02,361,Y,1,2015-04-25,49,2016-03-02,361,Y,Y,Visit 1,1,2015-05-08,62,2016-05-27,447,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-027,Clinical Site 02,2,36,F,Hispanic,Treatment B,TRTB,Completed,2015-03-08,2016-03-02,361,Y,1,2015-04-25,49,2016-03-02,361,Y,Y,Visit 1,1,2015-05-08,62,2016-05-27,447,45,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-027,Clinical Site 02,2,36,F,Hispanic,Treatment B,TRTB,Completed,2015-03-08,2016-03-02,361,Y,1,2015-04-25,49,2016-03-02,361,Y,Y,Visit 2,2,2015-06-22,107,2016-05-27,447,63,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-027,Clinical Site 02,2,36,F,Hispanic,Treatment B,TRTB,Completed,2015-03-08,2016-03-02,361,Y,1,2015-04-25,49,2016-03-02,361,Y,Y,Visit 3,3,2015-08-24,170,2016-05-27,447,66,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-027,Clinical Site 02,2,36,F,Hispanic,Treatment B,TRTB,Completed,2015-03-08,2016-03-02,361,Y,1,2015-04-25,49,2016-03-02,361,Y,Y,Unscheduled 4.1,4.1,2015-10-29,236,2016-05-27,447,43,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-027,Clinical Site 02,2,36,F,Hispanic,Treatment B,TRTB,Completed,2015-03-08,2016-03-02,361,Y,1,2015-04-25,49,2016-03-02,361,Y,Y,Visit 5,5,2015-12-11,279,2016-05-27,447,53,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-027,Clinical Site 02,2,36,F,Hispanic,Treatment B,TRTB,Completed,2015-03-08,2016-03-02,361,Y,1,2015-04-25,49,2016-03-02,361,Y,Y,Visit 6,6,2016-02-02,332,2016-05-27,447,31,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-027,Clinical Site 02,2,36,F,Hispanic,Treatment B,TRTB,Completed,2015-03-08,2016-03-02,361,Y,1,2015-04-25,49,2016-03-02,361,Y,Y,End of Study,7,2016-03-04,363,2016-05-27,447,84,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-028,Clinical Site 02,2,29,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-25,2015-12-12,232,Y,1,2015-06-18,55,2016-04-15,357,Y,N,Screening,0,2015-04-25,1,2015-12-11,231,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-028,Clinical Site 02,2,29,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-25,2015-12-12,232,Y,1,2015-06-18,55,2016-04-15,357,Y,N,Screening,0,2015-04-25,1,2015-12-11,231,48,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-028,Clinical Site 02,2,29,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-25,2015-12-12,232,Y,1,2015-06-18,55,2016-04-15,357,Y,N,Visit 1,1,2015-06-12,49,2015-12-11,231,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-028,Clinical Site 02,2,29,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-25,2015-12-12,232,Y,1,2015-06-18,55,2016-04-15,357,Y,N,Visit 1,1,2015-06-12,49,2015-12-11,231,70,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
02-028,Clinical Site 02,2,29,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-25,2015-12-12,232,Y,1,2015-06-18,55,2016-04-15,357,Y,N,Visit 2,2,2015-08-21,119,2015-12-11,231,43,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-028,Clinical Site 02,2,29,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-25,2015-12-12,232,Y,1,2015-06-18,55,2016-04-15,357,Y,N,Visit 3,3,2015-10-03,162,2015-12-11,231,69,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-029,Clinical Site 02,2,47,M,Black,Placebo,PLACEBO,Ongoing,2015-04-26,2016-04-15,356,Y,1,2015-06-17,53,2016-04-19,360,Y,Y,Screening,0,2015-04-26,1,2016-02-15,296,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
02-029,Clinical Site 02,2,47,M,Black,Placebo,PLACEBO,Ongoing,2015-04-26,2016-04-15,356,Y,1,2015-06-17,53,2016-04-19,360,Y,Y,Screening,0,2015-04-26,1,2016-02-15,296,115,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
02-029,Clinical Site 02,2,47,M,Black,Placebo,PLACEBO,Ongoing,2015-04-26,2016-04-15,356,Y,1,2015-06-17,53,2016-04-19,360,Y,Y,Visit 2,2,2015-08-19,116,2016-02-15,296,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
02-029,Clinical Site 02,2,47,M,Black,Placebo,PLACEBO,Ongoing,2015-04-26,2016-04-15,356,Y,1,2015-06-17,53,2016-04-19,360,Y,Y,Visit 2,2,2015-08-19,116,2016-02-15,296,48,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
02-029,Clinical Site 02,2,47,M,Black,Placebo,PLACEBO,Ongoing,2015-04-26,2016-04-15,356,Y,1,2015-06-17,53,2016-04-19,360,Y,Y,Visit 3,3,2015-10-06,164,2016-02-15,296,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
02-029,Clinical Site 02,2,47,M,Black,Placebo,PLACEBO,Ongoing,2015-04-26,2016-04-15,356,Y,1,2015-06-17,53,2016-04-19,360,Y,Y,Visit 3,3,2015-10-06,164,2016-02-15,296,66,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
02-029,Clinical Site 02,2,47,M,Black,Placebo,PLACEBO,Ongoing,2015-04-26,2016-04-15,356,Y,1,2015-06-17,53,2016-04-19,360,Y,Y,Visit 4,4,2015-12-11,230,2016-02-15,296,66,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-002,Clinical Site 03,3,27,F,White,Treatment A,TRTA,Completed,2015-09-02,2016-08-30,364,Y,1,2015-10-31,60,2016-09-04,369,Y,N,Screening,0,2015-09-02,1,2016-10-05,400,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-002,Clinical Site 03,3,27,F,White,Treatment A,TRTA,Completed,2015-09-02,2016-08-30,364,Y,1,2015-10-31,60,2016-09-04,369,Y,N,Screening,0,2015-09-02,1,2016-10-05,400,50,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-002,Clinical Site 03,3,27,F,White,Treatment A,TRTA,Completed,2015-09-02,2016-08-30,364,Y,1,2015-10-31,60,2016-09-04,369,Y,N,Visit 1,1,2015-10-22,51,2016-10-05,400,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-002,Clinical Site 03,3,27,F,White,Treatment A,TRTA,Completed,2015-09-02,2016-08-30,364,Y,1,2015-10-31,60,2016-09-04,369,Y,N,Visit 1,1,2015-10-22,51,2016-10-05,400,54,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-002,Clinical Site 03,3,27,F,White,Treatment A,TRTA,Completed,2015-09-02,2016-08-30,364,Y,1,2015-10-31,60,2016-09-04,369,Y,N,Visit 2,2,2015-12-15,105,2016-10-05,400,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-002,Clinical Site 03,3,27,F,White,Treatment A,TRTA,Completed,2015-09-02,2016-08-30,364,Y,1,2015-10-31,60,2016-09-04,369,Y,N,Visit 2,2,2015-12-15,105,2016-10-05,400,60,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-002,Clinical Site 03,3,27,F,White,Treatment A,TRTA,Completed,2015-09-02,2016-08-30,364,Y,1,2015-10-31,60,2016-09-04,369,Y,N,Visit 3,3,2016-02-13,165,2016-10-05,400,58,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-002,Clinical Site 03,3,27,F,White,Treatment A,TRTA,Completed,2015-09-02,2016-08-30,364,Y,1,2015-10-31,60,2016-09-04,369,Y,N,Visit 4,4,2016-04-11,223,2016-10-05,400,106,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-002,Clinical Site 03,3,27,F,White,Treatment A,TRTA,Completed,2015-09-02,2016-08-30,364,Y,1,2015-10-31,60,2016-09-04,369,Y,N,Visit 6,6,2016-07-26,329,2016-10-05,400,27,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
03-002,Clinical Site 03,3,27,F,White,Treatment A,TRTA,Completed,2015-09-02,2016-08-30,364,Y,1,2015-10-31,60,2016-09-04,369,Y,N,End of Study,7,2016-08-22,356,2016-10-05,400,44,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-003,Clinical Site 03,3,42,M,Black,Treatment B,TRTB,Ongoing,2015-05-26,2016-03-10,290,Y,1,2015-07-17,53,2016-05-29,370,Y,Y,Screening,0,2015-05-26,1,2016-03-08,288,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-003,Clinical Site 03,3,42,M,Black,Treatment B,TRTB,Ongoing,2015-05-26,2016-03-10,290,Y,1,2015-07-17,53,2016-05-29,370,Y,Y,Screening,0,2015-05-26,1,2016-03-08,288,49,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-003,Clinical Site 03,3,42,M,Black,Treatment B,TRTB,Ongoing,2015-05-26,2016-03-10,290,Y,1,2015-07-17,53,2016-05-29,370,Y,Y,Visit 1,1,2015-07-14,50,2016-03-08,288,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-003,Clinical Site 03,3,42,M,Black,Treatment B,TRTB,Ongoing,2015-05-26,2016-03-10,290,Y,1,2015-07-17,53,2016-05-29,370,Y,Y,Visit 1,1,2015-07-14,50,2016-03-08,288,59,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-003,Clinical Site 03,3,42,M,Black,Treatment B,TRTB,Ongoing,2015-05-26,2016-03-10,290,Y,1,2015-07-17,53,2016-05-29,370,Y,Y,Visit 2,2,2015-09-11,109,2016-03-08,288,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-003,Clinical Site 03,3,42,M,Black,Treatment B,TRTB,Ongoing,2015-05-26,2016-03-10,290,Y,1,2015-07-17,53,2016-05-29,370,Y,Y,Visit 2,2,2015-09-11,109,2016-03-08,288,53,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-003,Clinical Site 03,3,42,M,Black,Treatment B,TRTB,Ongoing,2015-05-26,2016-03-10,290,Y,1,2015-07-17,53,2016-05-29,370,Y,Y,Visit 3,3,2015-11-03,162,2016-03-08,288,8,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-003,Clinical Site 03,3,42,M,Black,Treatment B,TRTB,Ongoing,2015-05-26,2016-03-10,290,Y,1,2015-07-17,53,2016-05-29,370,Y,Y,Unscheduled 3.1,3.1,2015-11-11,170,2016-03-08,288,59,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-003,Clinical Site 03,3,42,M,Black,Treatment B,TRTB,Ongoing,2015-05-26,2016-03-10,290,Y,1,2015-07-17,53,2016-05-29,370,Y,Y,Visit 4,4,2016-01-09,229,2016-03-08,288,59,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-004,Clinical Site 03,3,19,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-03,2016-11-23,357,Y,1,2016-02-01,61,2016-12-10,374,N,Y,Screening,0,2015-12-03,1,2017-02-12,438,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-004,Clinical Site 03,3,19,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-03,2016-11-23,357,Y,1,2016-02-01,61,2016-12-10,374,N,Y,Screening,0,2015-12-03,1,2017-02-12,438,59,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-004,Clinical Site 03,3,19,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-03,2016-11-23,357,Y,1,2016-02-01,61,2016-12-10,374,N,Y,Visit 1,1,2016-01-31,60,2017-02-12,438,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-004,Clinical Site 03,3,19,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-03,2016-11-23,357,Y,1,2016-02-01,61,2016-12-10,374,N,Y,Visit 1,1,2016-01-31,60,2017-02-12,438,59,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
03-004,Clinical Site 03,3,19,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-03,2016-11-23,357,Y,1,2016-02-01,61,2016-12-10,374,N,Y,Visit 2,2,2016-03-30,119,2017-02-12,438,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-004,Clinical Site 03,3,19,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-03,2016-11-23,357,Y,1,2016-02-01,61,2016-12-10,374,N,Y,Visit 2,2,2016-03-30,119,2017-02-12,438,109,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-004,Clinical Site 03,3,19,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-03,2016-11-23,357,Y,1,2016-02-01,61,2016-12-10,374,N,Y,Visit 4,4,2016-07-17,228,2017-02-12,438,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-004,Clinical Site 03,3,19,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-03,2016-11-23,357,Y,1,2016-02-01,61,2016-12-10,374,N,Y,Visit 4,4,2016-07-17,228,2017-02-12,438,50,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
03-004,Clinical Site 03,3,19,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-03,2016-11-23,357,Y,1,2016-02-01,61,2016-12-10,374,N,Y,Visit 5,5,2016-09-05,278,2017-02-12,438,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-004,Clinical Site 03,3,19,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-03,2016-11-23,357,Y,1,2016-02-01,61,2016-12-10,374,N,Y,Visit 5,5,2016-09-05,278,2017-02-12,438,63,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-004,Clinical Site 03,3,19,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-03,2016-11-23,357,Y,1,2016-02-01,61,2016-12-10,374,N,Y,Visit 6,6,2016-11-07,341,2017-02-12,438,97,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-005,Clinical Site 03,3,48,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-15,2015-10-11,180,Y,1,2015-06-14,61,2016-04-22,374,Y,Y,Screening,0,2015-04-15,1,2015-12-13,243,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-005,Clinical Site 03,3,48,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-15,2015-10-11,180,Y,1,2015-06-14,61,2016-04-22,374,Y,Y,Screening,0,2015-04-15,1,2015-12-13,243,49,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-005,Clinical Site 03,3,48,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-15,2015-10-11,180,Y,1,2015-06-14,61,2016-04-22,374,Y,Y,Visit 1,1,2015-06-03,50,2015-12-13,243,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-005,Clinical Site 03,3,48,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-15,2015-10-11,180,Y,1,2015-06-14,61,2016-04-22,374,Y,Y,Visit 1,1,2015-06-03,50,2015-12-13,243,114,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-005,Clinical Site 03,3,48,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-15,2015-10-11,180,Y,1,2015-06-14,61,2016-04-22,374,Y,Y,Visit 3,3,2015-09-25,164,2015-12-13,243,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-005,Clinical Site 03,3,48,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-04-15,2015-10-11,180,Y,1,2015-06-14,61,2016-04-22,374,Y,Y,Visit 3,3,2015-09-25,164,2015-12-13,243,79,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-006,Clinical Site 03,3,52,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-05-24,2015-08-30,99,Y,1,2015-07-13,51,2016-05-16,359,Y,N,Screening,0,2015-05-24,1,2015-10-25,155,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-006,Clinical Site 03,3,52,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-05-24,2015-08-30,99,Y,1,2015-07-13,51,2016-05-16,359,Y,N,Screening,0,2015-05-24,1,2015-10-25,155,53,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-006,Clinical Site 03,3,52,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-05-24,2015-08-30,99,Y,1,2015-07-13,51,2016-05-16,359,Y,N,Visit 1,1,2015-07-16,54,2015-10-25,155,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-006,Clinical Site 03,3,52,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-05-24,2015-08-30,99,Y,1,2015-07-13,51,2016-05-16,359,Y,N,Visit 1,1,2015-07-16,54,2015-10-25,155,101,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
03-007,Clinical Site 03,3,49,F,Other/Mixed,Treatment A,TRTA,Completed,2015-08-18,2016-08-06,355,Y,1,2015-10-11,55,2016-08-16,365,Y,Y,Screening,0,2015-08-18,1,2016-10-01,411,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-007,Clinical Site 03,3,49,F,Other/Mixed,Treatment A,TRTA,Completed,2015-08-18,2016-08-06,355,Y,1,2015-10-11,55,2016-08-16,365,Y,Y,Screening,0,2015-08-18,1,2016-10-01,411,61,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-007,Clinical Site 03,3,49,F,Other/Mixed,Treatment A,TRTA,Completed,2015-08-18,2016-08-06,355,Y,1,2015-10-11,55,2016-08-16,365,Y,Y,Visit 1,1,2015-10-18,62,2016-10-01,411,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-007,Clinical Site 03,3,49,F,Other/Mixed,Treatment A,TRTA,Completed,2015-08-18,2016-08-06,355,Y,1,2015-10-11,55,2016-08-16,365,Y,Y,Visit 1,1,2015-10-18,62,2016-10-01,411,49,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-007,Clinical Site 03,3,49,F,Other/Mixed,Treatment A,TRTA,Completed,2015-08-18,2016-08-06,355,Y,1,2015-10-11,55,2016-08-16,365,Y,Y,Visit 2,2,2015-12-06,111,2016-10-01,411,57,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-007,Clinical Site 03,3,49,F,Other/Mixed,Treatment A,TRTA,Completed,2015-08-18,2016-08-06,355,Y,1,2015-10-11,55,2016-08-16,365,Y,Y,Visit 3,3,2016-02-01,168,2016-10-01,411,62,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
03-007,Clinical Site 03,3,49,F,Other/Mixed,Treatment A,TRTA,Completed,2015-08-18,2016-08-06,355,Y,1,2015-10-11,55,2016-08-16,365,Y,Y,Visit 4,4,2016-04-03,230,2016-10-01,411,101,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
03-007,Clinical Site 03,3,49,F,Other/Mixed,Treatment A,TRTA,Completed,2015-08-18,2016-08-06,355,Y,1,2015-10-11,55,2016-08-16,365,Y,Y,Visit 6,6,2016-07-13,331,2016-10-01,411,80,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-008,Clinical Site 03,3,46,M,Black,Treatment B,TRTB,Ongoing,2015-03-08,2016-02-17,347,Y,1,2015-04-25,49,2016-02-29,359,Y,N,Screening,0,2015-03-08,1,2016-04-21,411,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-008,Clinical Site 03,3,46,M,Black,Treatment B,TRTB,Ongoing,2015-03-08,2016-02-17,347,Y,1,2015-04-25,49,2016-02-29,359,Y,N,Screening,0,2015-03-08,1,2016-04-21,411,113,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-008,Clinical Site 03,3,46,M,Black,Treatment B,TRTB,Ongoing,2015-03-08,2016-02-17,347,Y,1,2015-04-25,49,2016-02-29,359,Y,N,Visit 2,2,2015-06-29,114,2016-04-21,411,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-008,Clinical Site 03,3,46,M,Black,Treatment B,TRTB,Ongoing,2015-03-08,2016-02-17,347,Y,1,2015-04-25,49,2016-02-29,359,Y,N,Visit 2,2,2015-06-29,114,2016-04-21,411,8,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-008,Clinical Site 03,3,46,M,Black,Treatment B,TRTB,Ongoing,2015-03-08,2016-02-17,347,Y,1,2015-04-25,49,2016-02-29,359,Y,N,Unscheduled 2.1,2.1,2015-07-07,122,2016-04-21,411,106,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
03-008,Clinical Site 03,3,46,M,Black,Treatment B,TRTB,Ongoing,2015-03-08,2016-02-17,347,Y,1,2015-04-25,49,2016-02-29,359,Y,N,Visit 4,4,2015-10-21,228,2016-04-21,411,103,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-008,Clinical Site 03,3,46,M,Black,Treatment B,TRTB,Ongoing,2015-03-08,2016-02-17,347,Y,1,2015-04-25,49,2016-02-29,359,Y,N,Visit 6,6,2016-02-01,331,2016-04-21,411,80,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
03-010,Clinical Site 03,3,40,M,White,Placebo,PLACEBO,Completed,2015-02-07,2016-02-13,372,Y,1,2015-04-06,59,2016-02-05,364,Y,Y,Screening,0,2015-02-07,1,2015-06-28,142,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-010,Clinical Site 03,3,40,M,White,Placebo,PLACEBO,Completed,2015-02-07,2016-02-13,372,Y,1,2015-04-06,59,2016-02-05,364,Y,Y,Screening,0,2015-02-07,1,2015-06-28,142,55,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-010,Clinical Site 03,3,40,M,White,Placebo,PLACEBO,Completed,2015-02-07,2016-02-13,372,Y,1,2015-04-06,59,2016-02-05,364,Y,Y,Visit 1,1,2015-04-03,56,2015-06-28,142,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-010,Clinical Site 03,3,40,M,White,Placebo,PLACEBO,Completed,2015-02-07,2016-02-13,372,Y,1,2015-04-06,59,2016-02-05,364,Y,Y,Visit 1,1,2015-04-03,56,2015-06-28,142,86,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-012,Clinical Site 03,3,32,M,Black,Placebo,PLACEBO,Ongoing,2015-08-19,2016-05-19,275,Y,1,2015-10-13,56,2016-08-22,370,N,Y,Screening,0,2015-08-19,1,2016-05-02,258,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-012,Clinical Site 03,3,32,M,Black,Placebo,PLACEBO,Ongoing,2015-08-19,2016-05-19,275,Y,1,2015-10-13,56,2016-08-22,370,N,Y,Screening,0,2015-08-19,1,2016-05-02,258,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-012,Clinical Site 03,3,32,M,Black,Placebo,PLACEBO,Ongoing,2015-08-19,2016-05-19,275,Y,1,2015-10-13,56,2016-08-22,370,N,Y,Unscheduled 0.1,0.1,2015-08-27,9,2016-05-02,258,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-012,Clinical Site 03,3,32,M,Black,Placebo,PLACEBO,Ongoing,2015-08-19,2016-05-19,275,Y,1,2015-10-13,56,2016-08-22,370,N,Y,Unscheduled 0.1,0.1,2015-08-27,9,2016-05-02,258,42,RECIST 1.1,Best Overall Response (RECIST 1.1),NE,4,#969696
03-012,Clinical Site 03,3,32,M,Black,Placebo,PLACEBO,Ongoing,2015-08-19,2016-05-19,275,Y,1,2015-10-13,56,2016-08-22,370,N,Y,Visit 1,1,2015-10-08,51,2016-05-02,258,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-012,Clinical Site 03,3,32,M,Black,Placebo,PLACEBO,Ongoing,2015-08-19,2016-05-19,275,Y,1,2015-10-13,56,2016-08-22,370,N,Y,Visit 1,1,2015-10-08,51,2016-05-02,258,68,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-012,Clinical Site 03,3,32,M,Black,Placebo,PLACEBO,Ongoing,2015-08-19,2016-05-19,275,Y,1,2015-10-13,56,2016-08-22,370,N,Y,Visit 2,2,2015-12-15,119,2016-05-02,258,44,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
03-012,Clinical Site 03,3,32,M,Black,Placebo,PLACEBO,Ongoing,2015-08-19,2016-05-19,275,Y,1,2015-10-13,56,2016-08-22,370,N,Y,Visit 3,3,2016-01-28,163,2016-05-02,258,95,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-013,Clinical Site 03,3,33,M,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-10-28,2016-08-19,297,Y,1,2015-12-21,55,2016-10-20,359,Y,Y,Screening,0,2015-10-28,1,2016-08-02,280,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-013,Clinical Site 03,3,33,M,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-10-28,2016-08-19,297,Y,1,2015-12-21,55,2016-10-20,359,Y,Y,Screening,0,2015-10-28,1,2016-08-02,280,113,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-013,Clinical Site 03,3,33,M,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-10-28,2016-08-19,297,Y,1,2015-12-21,55,2016-10-20,359,Y,Y,Visit 2,2,2016-02-18,114,2016-08-02,280,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-013,Clinical Site 03,3,33,M,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-10-28,2016-08-19,297,Y,1,2015-12-21,55,2016-10-20,359,Y,Y,Visit 2,2,2016-02-18,114,2016-08-02,280,114,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-013,Clinical Site 03,3,33,M,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-10-28,2016-08-19,297,Y,1,2015-12-21,55,2016-10-20,359,Y,Y,Visit 4,4,2016-06-11,228,2016-08-02,280,52,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-014,Clinical Site 03,3,53,F,Black,Placebo,PLACEBO,Ongoing,2015-02-06,2015-03-07,30,Y,1,2015-04-09,63,2016-01-26,355,Y,Y,Screening,0,2015-02-06,1,2015-04-21,75,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-014,Clinical Site 03,3,53,F,Black,Placebo,PLACEBO,Ongoing,2015-02-06,2015-03-07,30,Y,1,2015-04-09,63,2016-01-26,355,Y,Y,Screening,0,2015-02-06,1,2015-04-21,75,74,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-015,Clinical Site 03,3,24,F,Black,Placebo,PLACEBO,Completed,2015-07-21,2016-07-13,359,Y,1,2015-09-17,59,2016-07-28,374,Y,Y,Screening,0,2015-07-21,1,2016-01-19,183,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-015,Clinical Site 03,3,24,F,Black,Placebo,PLACEBO,Completed,2015-07-21,2016-07-13,359,Y,1,2015-09-17,59,2016-07-28,374,Y,Y,Screening,0,2015-07-21,1,2016-01-19,183,54,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-015,Clinical Site 03,3,24,F,Black,Placebo,PLACEBO,Completed,2015-07-21,2016-07-13,359,Y,1,2015-09-17,59,2016-07-28,374,Y,Y,Visit 1,1,2015-09-13,55,2016-01-19,183,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-015,Clinical Site 03,3,24,F,Black,Placebo,PLACEBO,Completed,2015-07-21,2016-07-13,359,Y,1,2015-09-17,59,2016-07-28,374,Y,Y,Visit 1,1,2015-09-13,55,2016-01-19,183,50,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
03-015,Clinical Site 03,3,24,F,Black,Placebo,PLACEBO,Completed,2015-07-21,2016-07-13,359,Y,1,2015-09-17,59,2016-07-28,374,Y,Y,Visit 2,2,2015-11-02,105,2016-01-19,183,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-015,Clinical Site 03,3,24,F,Black,Placebo,PLACEBO,Completed,2015-07-21,2016-07-13,359,Y,1,2015-09-17,59,2016-07-28,374,Y,Y,Visit 2,2,2015-11-02,105,2016-01-19,183,78,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-016,Clinical Site 03,3,20,F,White,Treatment A,TRTA,Ongoing,2015-05-04,2015-07-04,62,Y,1,2015-06-30,58,2016-04-22,355,Y,N,Screening,0,2015-05-04,1,2015-09-30,150,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-016,Clinical Site 03,3,20,F,White,Treatment A,TRTA,Ongoing,2015-05-04,2015-07-04,62,Y,1,2015-06-30,58,2016-04-22,355,Y,N,Screening,0,2015-05-04,1,2015-09-30,150,59,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-016,Clinical Site 03,3,20,F,White,Treatment A,TRTA,Ongoing,2015-05-04,2015-07-04,62,Y,1,2015-06-30,58,2016-04-22,355,Y,N,Unscheduled 1.1,1.1,2015-07-02,60,2015-09-30,150,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-016,Clinical Site 03,3,20,F,White,Treatment A,TRTA,Ongoing,2015-05-04,2015-07-04,62,Y,1,2015-06-30,58,2016-04-22,355,Y,N,Unscheduled 1.1,1.1,2015-07-02,60,2015-09-30,150,90,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-017,Clinical Site 03,3,43,M,Black,Treatment B,TRTB,Ongoing,2015-06-26,2015-10-27,124,Y,1,2015-08-14,50,2016-06-20,361,Y,Y,Screening,0,2015-06-26,1,2015-09-19,86,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-017,Clinical Site 03,3,43,M,Black,Treatment B,TRTB,Ongoing,2015-06-26,2015-10-27,124,Y,1,2015-08-14,50,2016-06-20,361,Y,Y,Screening,0,2015-06-26,1,2015-09-19,86,53,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-017,Clinical Site 03,3,43,M,Black,Treatment B,TRTB,Ongoing,2015-06-26,2015-10-27,124,Y,1,2015-08-14,50,2016-06-20,361,Y,Y,Visit 1,1,2015-08-18,54,2015-09-19,86,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-017,Clinical Site 03,3,43,M,Black,Treatment B,TRTB,Ongoing,2015-06-26,2015-10-27,124,Y,1,2015-08-14,50,2016-06-20,361,Y,Y,Visit 1,1,2015-08-18,54,2015-09-19,86,32,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-018,Clinical Site 03,3,19,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-30,2015-08-30,93,Y,1,2015-07-20,52,2016-06-05,373,N,Y,Screening,0,2015-05-30,1,2015-09-25,119,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-018,Clinical Site 03,3,19,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-30,2015-08-30,93,Y,1,2015-07-20,52,2016-06-05,373,N,Y,Screening,0,2015-05-30,1,2015-09-25,119,57,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-018,Clinical Site 03,3,19,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-30,2015-08-30,93,Y,1,2015-07-20,52,2016-06-05,373,N,Y,Visit 1,1,2015-07-26,58,2015-09-25,119,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-018,Clinical Site 03,3,19,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-30,2015-08-30,93,Y,1,2015-07-20,52,2016-06-05,373,N,Y,Visit 1,1,2015-07-26,58,2015-09-25,119,8,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
03-018,Clinical Site 03,3,19,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-30,2015-08-30,93,Y,1,2015-07-20,52,2016-06-05,373,N,Y,Unscheduled 1.1,1.1,2015-08-03,66,2015-09-25,119,53,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Screening,0,2015-11-06,1,2017-02-11,464,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Screening,0,2015-11-06,1,2017-02-11,464,57,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 1,1,2016-01-02,58,2017-02-11,464,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 1,1,2016-01-02,58,2017-02-11,464,56,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 2,2,2016-02-27,114,2017-02-11,464,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 2,2,2016-02-27,114,2017-02-11,464,52,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 3,3,2016-04-19,166,2017-02-11,464,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 3,3,2016-04-19,166,2017-02-11,464,53,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 4,4,2016-06-11,219,2017-02-11,464,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 4,4,2016-06-11,219,2017-02-11,464,62,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 5,5,2016-08-12,281,2017-02-11,464,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 5,5,2016-08-12,281,2017-02-11,464,59,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 6,6,2016-10-10,340,2017-02-11,464,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,Visit 6,6,2016-10-10,340,2017-02-11,464,34,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-019,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Completed,2015-11-06,2016-11-07,368,Y,1,2016-01-05,61,2016-10-25,355,N,Y,End of Study,7,2016-11-13,374,2017-02-11,464,90,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-020,Clinical Site 03,3,50,M,White,Treatment A,TRTA,Ongoing,2015-08-09,2015-12-09,123,Y,1,2015-09-27,50,2016-07-31,358,Y,Y,Screening,0,2015-08-09,1,2015-11-16,100,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-020,Clinical Site 03,3,50,M,White,Treatment A,TRTA,Ongoing,2015-08-09,2015-12-09,123,Y,1,2015-09-27,50,2016-07-31,358,Y,Y,Screening,0,2015-08-09,1,2015-11-16,100,62,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-020,Clinical Site 03,3,50,M,White,Treatment A,TRTA,Ongoing,2015-08-09,2015-12-09,123,Y,1,2015-09-27,50,2016-07-31,358,Y,Y,Visit 1,1,2015-10-10,63,2015-11-16,100,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-020,Clinical Site 03,3,50,M,White,Treatment A,TRTA,Ongoing,2015-08-09,2015-12-09,123,Y,1,2015-09-27,50,2016-07-31,358,Y,Y,Visit 1,1,2015-10-10,63,2015-11-16,100,37,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-021,Clinical Site 03,3,18,M,Hispanic,Treatment A,TRTA,Ongoing,2015-09-21,2016-08-09,324,Y,1,2015-11-12,53,2016-09-11,357,Y,Y,Screening,0,2015-09-21,1,2016-04-07,200,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-021,Clinical Site 03,3,18,M,Hispanic,Treatment A,TRTA,Ongoing,2015-09-21,2016-08-09,324,Y,1,2015-11-12,53,2016-09-11,357,Y,Y,Screening,0,2015-09-21,1,2016-04-07,200,62,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-021,Clinical Site 03,3,18,M,Hispanic,Treatment A,TRTA,Ongoing,2015-09-21,2016-08-09,324,Y,1,2015-11-12,53,2016-09-11,357,Y,Y,Visit 1,1,2015-11-22,63,2016-04-07,200,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-021,Clinical Site 03,3,18,M,Hispanic,Treatment A,TRTA,Ongoing,2015-09-21,2016-08-09,324,Y,1,2015-11-12,53,2016-09-11,357,Y,Y,Visit 1,1,2015-11-22,63,2016-04-07,200,45,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
03-021,Clinical Site 03,3,18,M,Hispanic,Treatment A,TRTA,Ongoing,2015-09-21,2016-08-09,324,Y,1,2015-11-12,53,2016-09-11,357,Y,Y,Visit 2,2,2016-01-06,108,2016-04-07,200,92,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-022,Clinical Site 03,3,49,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-14,2016-04-14,337,Y,1,2015-07-02,50,2016-05-18,371,Y,Y,Screening,0,2015-05-14,1,2016-05-24,377,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-022,Clinical Site 03,3,49,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-14,2016-04-14,337,Y,1,2015-07-02,50,2016-05-18,371,Y,Y,Screening,0,2015-05-14,1,2016-05-24,377,56,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-022,Clinical Site 03,3,49,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-14,2016-04-14,337,Y,1,2015-07-02,50,2016-05-18,371,Y,Y,Visit 1,1,2015-07-09,57,2016-05-24,377,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-022,Clinical Site 03,3,49,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-14,2016-04-14,337,Y,1,2015-07-02,50,2016-05-18,371,Y,Y,Visit 1,1,2015-07-09,57,2016-05-24,377,54,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
03-022,Clinical Site 03,3,49,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-14,2016-04-14,337,Y,1,2015-07-02,50,2016-05-18,371,Y,Y,Visit 2,2,2015-09-01,111,2016-05-24,377,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-022,Clinical Site 03,3,49,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-14,2016-04-14,337,Y,1,2015-07-02,50,2016-05-18,371,Y,Y,Visit 2,2,2015-09-01,111,2016-05-24,377,56,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-022,Clinical Site 03,3,49,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-14,2016-04-14,337,Y,1,2015-07-02,50,2016-05-18,371,Y,Y,Visit 3,3,2015-10-27,167,2016-05-24,377,53,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-022,Clinical Site 03,3,49,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-14,2016-04-14,337,Y,1,2015-07-02,50,2016-05-18,371,Y,Y,Visit 4,4,2015-12-19,220,2016-05-24,377,66,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-022,Clinical Site 03,3,49,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-05-14,2016-04-14,337,Y,1,2015-07-02,50,2016-05-18,371,Y,Y,Visit 5,5,2016-02-23,286,2016-05-24,377,91,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-023,Clinical Site 03,3,52,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-03-25,2015-06-03,71,Y,1,2015-05-25,62,2016-03-15,357,Y,Y,Screening,0,2015-03-25,1,2015-06-26,94,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-023,Clinical Site 03,3,52,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-03-25,2015-06-03,71,Y,1,2015-05-25,62,2016-03-15,357,Y,Y,Screening,0,2015-03-25,1,2015-06-26,94,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-023,Clinical Site 03,3,52,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-03-25,2015-06-03,71,Y,1,2015-05-25,62,2016-03-15,357,Y,Y,Unscheduled 0.1,0.1,2015-04-02,9,2015-06-26,94,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-023,Clinical Site 03,3,52,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-03-25,2015-06-03,71,Y,1,2015-05-25,62,2016-03-15,357,Y,Y,Unscheduled 0.1,0.1,2015-04-02,9,2015-06-26,94,85,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-025,Clinical Site 03,3,53,F,Black,Treatment B,TRTB,Ongoing,2015-04-29,2016-02-16,294,Y,1,2015-06-24,57,2016-05-05,373,Y,N,Screening,0,2015-04-29,1,2016-05-04,372,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-025,Clinical Site 03,3,53,F,Black,Treatment B,TRTB,Ongoing,2015-04-29,2016-02-16,294,Y,1,2015-06-24,57,2016-05-05,373,Y,N,Screening,0,2015-04-29,1,2016-05-04,372,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-025,Clinical Site 03,3,53,F,Black,Treatment B,TRTB,Ongoing,2015-04-29,2016-02-16,294,Y,1,2015-06-24,57,2016-05-05,373,Y,N,Unscheduled 0.1,0.1,2015-05-07,9,2016-05-04,372,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-025,Clinical Site 03,3,53,F,Black,Treatment B,TRTB,Ongoing,2015-04-29,2016-02-16,294,Y,1,2015-06-24,57,2016-05-05,373,Y,N,Unscheduled 0.1,0.1,2015-05-07,9,2016-05-04,372,53,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
03-025,Clinical Site 03,3,53,F,Black,Treatment B,TRTB,Ongoing,2015-04-29,2016-02-16,294,Y,1,2015-06-24,57,2016-05-05,373,Y,N,Visit 1,1,2015-06-29,62,2016-05-04,372,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-025,Clinical Site 03,3,53,F,Black,Treatment B,TRTB,Ongoing,2015-04-29,2016-02-16,294,Y,1,2015-06-24,57,2016-05-05,373,Y,N,Visit 1,1,2015-06-29,62,2016-05-04,372,43,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-025,Clinical Site 03,3,53,F,Black,Treatment B,TRTB,Ongoing,2015-04-29,2016-02-16,294,Y,1,2015-06-24,57,2016-05-05,373,Y,N,Visit 2,2,2015-08-11,105,2016-05-04,372,61,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-025,Clinical Site 03,3,53,F,Black,Treatment B,TRTB,Ongoing,2015-04-29,2016-02-16,294,Y,1,2015-06-24,57,2016-05-05,373,Y,N,Visit 3,3,2015-10-11,166,2016-05-04,372,110,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
03-025,Clinical Site 03,3,53,F,Black,Treatment B,TRTB,Ongoing,2015-04-29,2016-02-16,294,Y,1,2015-06-24,57,2016-05-05,373,Y,N,Visit 5,5,2016-01-29,276,2016-05-04,372,96,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-026,Clinical Site 03,3,18,M,White,Treatment B,TRTB,Ongoing,2015-10-08,2015-10-28,21,Y,1,2015-12-02,56,2016-10-16,375,Y,Y,Screening,0,2015-10-08,1,2015-12-12,66,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-026,Clinical Site 03,3,18,M,White,Treatment B,TRTB,Ongoing,2015-10-08,2015-10-28,21,Y,1,2015-12-02,56,2016-10-16,375,Y,Y,Screening,0,2015-10-08,1,2015-12-12,66,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-026,Clinical Site 03,3,18,M,White,Treatment B,TRTB,Ongoing,2015-10-08,2015-10-28,21,Y,1,2015-12-02,56,2016-10-16,375,Y,Y,Unscheduled 0.1,0.1,2015-10-16,9,2015-12-12,66,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-026,Clinical Site 03,3,18,M,White,Treatment B,TRTB,Ongoing,2015-10-08,2015-10-28,21,Y,1,2015-12-02,56,2016-10-16,375,Y,Y,Unscheduled 0.1,0.1,2015-10-16,9,2015-12-12,66,57,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-027,Clinical Site 03,3,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-05-10,2015-05-25,16,Y,1,2015-07-06,58,2016-05-10,367,Y,Y,Screening,0,2015-05-10,1,2015-06-15,37,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-027,Clinical Site 03,3,37,F,Other/Mixed,Treatment B,TRTB,Ongoing,2015-05-10,2015-05-25,16,Y,1,2015-07-06,58,2016-05-10,367,Y,Y,Screening,0,2015-05-10,1,2015-06-15,37,36,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-028,Clinical Site 03,3,37,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-03-08,2015-11-22,260,Y,1,2015-05-02,56,2016-03-06,365,Y,Y,Screening,0,2015-03-08,1,2015-11-10,248,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-028,Clinical Site 03,3,37,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-03-08,2015-11-22,260,Y,1,2015-05-02,56,2016-03-06,365,Y,Y,Screening,0,2015-03-08,1,2015-11-10,248,59,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-028,Clinical Site 03,3,37,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-03-08,2015-11-22,260,Y,1,2015-05-02,56,2016-03-06,365,Y,Y,Visit 1,1,2015-05-06,60,2015-11-10,248,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-028,Clinical Site 03,3,37,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-03-08,2015-11-22,260,Y,1,2015-05-02,56,2016-03-06,365,Y,Y,Visit 1,1,2015-05-06,60,2015-11-10,248,46,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-028,Clinical Site 03,3,37,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-03-08,2015-11-22,260,Y,1,2015-05-02,56,2016-03-06,365,Y,Y,Visit 2,2,2015-06-21,106,2015-11-10,248,65,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-028,Clinical Site 03,3,37,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-03-08,2015-11-22,260,Y,1,2015-05-02,56,2016-03-06,365,Y,Y,Visit 3,3,2015-08-25,171,2015-11-10,248,77,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-029,Clinical Site 03,3,26,M,White,Placebo,PLACEBO,Ongoing,2015-06-03,2016-02-24,267,Y,1,2015-07-31,59,2016-06-07,371,Y,N,Screening,0,2015-06-03,1,2016-01-21,233,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-029,Clinical Site 03,3,26,M,White,Placebo,PLACEBO,Ongoing,2015-06-03,2016-02-24,267,Y,1,2015-07-31,59,2016-06-07,371,Y,N,Screening,0,2015-06-03,1,2016-01-21,233,51,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-029,Clinical Site 03,3,26,M,White,Placebo,PLACEBO,Ongoing,2015-06-03,2016-02-24,267,Y,1,2015-07-31,59,2016-06-07,371,Y,N,Visit 1,1,2015-07-24,52,2016-01-21,233,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-029,Clinical Site 03,3,26,M,White,Placebo,PLACEBO,Ongoing,2015-06-03,2016-02-24,267,Y,1,2015-07-31,59,2016-06-07,371,Y,N,Visit 1,1,2015-07-24,52,2016-01-21,233,65,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-029,Clinical Site 03,3,26,M,White,Placebo,PLACEBO,Ongoing,2015-06-03,2016-02-24,267,Y,1,2015-07-31,59,2016-06-07,371,Y,N,Visit 2,2,2015-09-27,117,2016-01-21,233,54,RECIST 1.1,Best Overall Response (RECIST 1.1),NE,4,#969696
03-029,Clinical Site 03,3,26,M,White,Placebo,PLACEBO,Ongoing,2015-06-03,2016-02-24,267,Y,1,2015-07-31,59,2016-06-07,371,Y,N,Visit 3,3,2015-11-20,171,2016-01-21,233,62,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
03-030,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Ongoing,2015-03-30,2015-12-19,265,Y,1,2015-05-29,61,2016-03-20,357,Y,Y,Screening,0,2015-03-30,1,2015-09-26,181,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
03-030,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Ongoing,2015-03-30,2015-12-19,265,Y,1,2015-05-29,61,2016-03-20,357,Y,Y,Screening,0,2015-03-30,1,2015-09-26,181,59,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
03-030,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Ongoing,2015-03-30,2015-12-19,265,Y,1,2015-05-29,61,2016-03-20,357,Y,Y,Visit 1,1,2015-05-28,60,2015-09-26,181,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-030,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Ongoing,2015-03-30,2015-12-19,265,Y,1,2015-05-29,61,2016-03-20,357,Y,Y,Visit 1,1,2015-05-28,60,2015-09-26,181,8,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-030,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Ongoing,2015-03-30,2015-12-19,265,Y,1,2015-05-29,61,2016-03-20,357,Y,Y,Unscheduled 1.1,1.1,2015-06-05,68,2015-09-26,181,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
03-030,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Ongoing,2015-03-30,2015-12-19,265,Y,1,2015-05-29,61,2016-03-20,357,Y,Y,Unscheduled 1.1,1.1,2015-06-05,68,2015-09-26,181,37,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
03-030,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Ongoing,2015-03-30,2015-12-19,265,Y,1,2015-05-29,61,2016-03-20,357,Y,Y,Visit 2,2,2015-07-12,105,2015-09-26,181,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
03-030,Clinical Site 03,3,18,M,Hispanic,Treatment B,TRTB,Ongoing,2015-03-30,2015-12-19,265,Y,1,2015-05-29,61,2016-03-20,357,Y,Y,Visit 2,2,2015-07-12,105,2015-09-26,181,76,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-002,Clinical Site 04,4,54,F,White,Treatment A,TRTA,Completed,2015-06-19,2016-06-09,357,Y,1,2015-08-15,58,2016-06-07,355,Y,Y,Screening,0,2015-06-19,1,2015-11-27,162,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-002,Clinical Site 04,4,54,F,White,Treatment A,TRTA,Completed,2015-06-19,2016-06-09,357,Y,1,2015-08-15,58,2016-06-07,355,Y,Y,Screening,0,2015-06-19,1,2015-11-27,162,53,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-002,Clinical Site 04,4,54,F,White,Treatment A,TRTA,Completed,2015-06-19,2016-06-09,357,Y,1,2015-08-15,58,2016-06-07,355,Y,Y,Visit 1,1,2015-08-11,54,2015-11-27,162,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-002,Clinical Site 04,4,54,F,White,Treatment A,TRTA,Completed,2015-06-19,2016-06-09,357,Y,1,2015-08-15,58,2016-06-07,355,Y,Y,Visit 1,1,2015-08-11,54,2015-11-27,162,8,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-002,Clinical Site 04,4,54,F,White,Treatment A,TRTA,Completed,2015-06-19,2016-06-09,357,Y,1,2015-08-15,58,2016-06-07,355,Y,Y,Unscheduled 1.1,1.1,2015-08-19,62,2015-11-27,162,100,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-003,Clinical Site 04,4,25,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-11-17,2015-12-30,44,Y,1,2016-01-05,50,2016-11-13,363,Y,Y,Screening,0,2015-11-17,1,2016-03-03,108,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-003,Clinical Site 04,4,25,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-11-17,2015-12-30,44,Y,1,2016-01-05,50,2016-11-13,363,Y,Y,Screening,0,2015-11-17,1,2016-03-03,108,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-003,Clinical Site 04,4,25,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-11-17,2015-12-30,44,Y,1,2016-01-05,50,2016-11-13,363,Y,Y,Unscheduled 0.1,0.1,2015-11-25,9,2016-03-03,108,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-003,Clinical Site 04,4,25,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-11-17,2015-12-30,44,Y,1,2016-01-05,50,2016-11-13,363,Y,Y,Unscheduled 0.1,0.1,2015-11-25,9,2016-03-03,108,99,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-004,Clinical Site 04,4,39,M,Black,Placebo,PLACEBO,Ongoing,2015-08-03,2016-01-10,161,Y,1,2015-09-28,57,2016-07-26,359,Y,Y,Screening,0,2015-08-03,1,2016-02-20,202,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-004,Clinical Site 04,4,39,M,Black,Placebo,PLACEBO,Ongoing,2015-08-03,2016-01-10,161,Y,1,2015-09-28,57,2016-07-26,359,Y,Y,Screening,0,2015-08-03,1,2016-02-20,202,61,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-004,Clinical Site 04,4,39,M,Black,Placebo,PLACEBO,Ongoing,2015-08-03,2016-01-10,161,Y,1,2015-09-28,57,2016-07-26,359,Y,Y,Visit 1,1,2015-10-03,62,2016-02-20,202,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
04-004,Clinical Site 04,4,39,M,Black,Placebo,PLACEBO,Ongoing,2015-08-03,2016-01-10,161,Y,1,2015-09-28,57,2016-07-26,359,Y,Y,Visit 1,1,2015-10-03,62,2016-02-20,202,8,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-004,Clinical Site 04,4,39,M,Black,Placebo,PLACEBO,Ongoing,2015-08-03,2016-01-10,161,Y,1,2015-09-28,57,2016-07-26,359,Y,Y,Unscheduled 1.1,1.1,2015-10-11,70,2016-02-20,202,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-004,Clinical Site 04,4,39,M,Black,Placebo,PLACEBO,Ongoing,2015-08-03,2016-01-10,161,Y,1,2015-09-28,57,2016-07-26,359,Y,Y,Unscheduled 1.1,1.1,2015-10-11,70,2016-02-20,202,35,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-004,Clinical Site 04,4,39,M,Black,Placebo,PLACEBO,Ongoing,2015-08-03,2016-01-10,161,Y,1,2015-09-28,57,2016-07-26,359,Y,Y,Visit 2,2,2015-11-15,105,2016-02-20,202,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-004,Clinical Site 04,4,39,M,Black,Placebo,PLACEBO,Ongoing,2015-08-03,2016-01-10,161,Y,1,2015-09-28,57,2016-07-26,359,Y,Y,Visit 2,2,2015-11-15,105,2016-02-20,202,97,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-005,Clinical Site 04,4,42,M,White,Treatment B,TRTB,Completed,2015-08-17,2016-08-20,370,Y,1,2015-10-15,60,2016-08-13,363,Y,Y,Screening,0,2015-08-17,1,2016-10-09,420,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-005,Clinical Site 04,4,42,M,White,Treatment B,TRTB,Completed,2015-08-17,2016-08-20,370,Y,1,2015-10-15,60,2016-08-13,363,Y,Y,Screening,0,2015-08-17,1,2016-10-09,420,49,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-005,Clinical Site 04,4,42,M,White,Treatment B,TRTB,Completed,2015-08-17,2016-08-20,370,Y,1,2015-10-15,60,2016-08-13,363,Y,Y,Visit 1,1,2015-10-05,50,2016-10-09,420,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-005,Clinical Site 04,4,42,M,White,Treatment B,TRTB,Completed,2015-08-17,2016-08-20,370,Y,1,2015-10-15,60,2016-08-13,363,Y,Y,Visit 1,1,2015-10-05,50,2016-10-09,420,68,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-005,Clinical Site 04,4,42,M,White,Treatment B,TRTB,Completed,2015-08-17,2016-08-20,370,Y,1,2015-10-15,60,2016-08-13,363,Y,Y,Visit 2,2,2015-12-12,118,2016-10-09,420,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-005,Clinical Site 04,4,42,M,White,Treatment B,TRTB,Completed,2015-08-17,2016-08-20,370,Y,1,2015-10-15,60,2016-08-13,363,Y,Y,Visit 2,2,2015-12-12,118,2016-10-09,420,50,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-005,Clinical Site 04,4,42,M,White,Treatment B,TRTB,Completed,2015-08-17,2016-08-20,370,Y,1,2015-10-15,60,2016-08-13,363,Y,Y,Visit 3,3,2016-01-31,168,2016-10-09,420,57,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-005,Clinical Site 04,4,42,M,White,Treatment B,TRTB,Completed,2015-08-17,2016-08-20,370,Y,1,2015-10-15,60,2016-08-13,363,Y,Y,Visit 4,4,2016-03-28,225,2016-10-09,420,55,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-005,Clinical Site 04,4,42,M,White,Treatment B,TRTB,Completed,2015-08-17,2016-08-20,370,Y,1,2015-10-15,60,2016-08-13,363,Y,Y,Visit 5,5,2016-05-22,280,2016-10-09,420,60,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-005,Clinical Site 04,4,42,M,White,Treatment B,TRTB,Completed,2015-08-17,2016-08-20,370,Y,1,2015-10-15,60,2016-08-13,363,Y,Y,Visit 6,6,2016-07-21,340,2016-10-09,420,26,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-005,Clinical Site 04,4,42,M,White,Treatment B,TRTB,Completed,2015-08-17,2016-08-20,370,Y,1,2015-10-15,60,2016-08-13,363,Y,Y,End of Study,7,2016-08-16,366,2016-10-09,420,54,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-007,Clinical Site 04,4,24,M,Hispanic,Treatment B,TRTB,Completed,2015-04-15,2016-04-08,360,Y,1,2015-06-07,54,2016-04-15,367,Y,Y,Screening,0,2015-04-15,1,2015-11-26,226,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-007,Clinical Site 04,4,24,M,Hispanic,Treatment B,TRTB,Completed,2015-04-15,2016-04-08,360,Y,1,2015-06-07,54,2016-04-15,367,Y,Y,Screening,0,2015-04-15,1,2015-11-26,226,50,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-007,Clinical Site 04,4,24,M,Hispanic,Treatment B,TRTB,Completed,2015-04-15,2016-04-08,360,Y,1,2015-06-07,54,2016-04-15,367,Y,Y,Visit 1,1,2015-06-04,51,2015-11-26,226,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-007,Clinical Site 04,4,24,M,Hispanic,Treatment B,TRTB,Completed,2015-04-15,2016-04-08,360,Y,1,2015-06-07,54,2016-04-15,367,Y,Y,Visit 1,1,2015-06-04,51,2015-11-26,226,62,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-007,Clinical Site 04,4,24,M,Hispanic,Treatment B,TRTB,Completed,2015-04-15,2016-04-08,360,Y,1,2015-06-07,54,2016-04-15,367,Y,Y,Visit 2,2,2015-08-05,113,2015-11-26,226,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-007,Clinical Site 04,4,24,M,Hispanic,Treatment B,TRTB,Completed,2015-04-15,2016-04-08,360,Y,1,2015-06-07,54,2016-04-15,367,Y,Y,Visit 2,2,2015-08-05,113,2015-11-26,226,55,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-007,Clinical Site 04,4,24,M,Hispanic,Treatment B,TRTB,Completed,2015-04-15,2016-04-08,360,Y,1,2015-06-07,54,2016-04-15,367,Y,Y,Visit 3,3,2015-09-29,168,2015-11-26,226,58,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-008,Clinical Site 04,4,31,F,Black,Placebo,PLACEBO,Completed,2015-04-10,2016-04-02,359,Y,1,2015-06-02,54,2016-04-18,375,Y,Y,Screening,0,2015-04-10,1,2016-01-08,274,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-008,Clinical Site 04,4,31,F,Black,Placebo,PLACEBO,Completed,2015-04-10,2016-04-02,359,Y,1,2015-06-02,54,2016-04-18,375,Y,Y,Screening,0,2015-04-10,1,2016-01-08,274,58,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-008,Clinical Site 04,4,31,F,Black,Placebo,PLACEBO,Completed,2015-04-10,2016-04-02,359,Y,1,2015-06-02,54,2016-04-18,375,Y,Y,Visit 1,1,2015-06-07,59,2016-01-08,274,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-008,Clinical Site 04,4,31,F,Black,Placebo,PLACEBO,Completed,2015-04-10,2016-04-02,359,Y,1,2015-06-02,54,2016-04-18,375,Y,Y,Visit 1,1,2015-06-07,59,2016-01-08,274,52,RECIST 1.1,Best Overall Response (RECIST 1.1),NE,4,#969696
04-008,Clinical Site 04,4,31,F,Black,Placebo,PLACEBO,Completed,2015-04-10,2016-04-02,359,Y,1,2015-06-02,54,2016-04-18,375,Y,Y,Visit 2,2,2015-07-29,111,2016-01-08,274,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-008,Clinical Site 04,4,31,F,Black,Placebo,PLACEBO,Completed,2015-04-10,2016-04-02,359,Y,1,2015-06-02,54,2016-04-18,375,Y,Y,Visit 2,2,2015-07-29,111,2016-01-08,274,54,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-008,Clinical Site 04,4,31,F,Black,Placebo,PLACEBO,Completed,2015-04-10,2016-04-02,359,Y,1,2015-06-02,54,2016-04-18,375,Y,Y,Visit 3,3,2015-09-21,165,2016-01-08,274,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-008,Clinical Site 04,4,31,F,Black,Placebo,PLACEBO,Completed,2015-04-10,2016-04-02,359,Y,1,2015-06-02,54,2016-04-18,375,Y,Y,Visit 3,3,2015-09-21,165,2016-01-08,274,57,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-008,Clinical Site 04,4,31,F,Black,Placebo,PLACEBO,Completed,2015-04-10,2016-04-02,359,Y,1,2015-06-02,54,2016-04-18,375,Y,Y,Visit 4,4,2015-11-17,222,2016-01-08,274,52,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-009,Clinical Site 04,4,39,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-01-22,2015-10-27,279,Y,1,2015-03-21,59,2016-01-30,374,Y,Y,Screening,0,2015-01-22,1,2015-08-21,212,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-009,Clinical Site 04,4,39,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-01-22,2015-10-27,279,Y,1,2015-03-21,59,2016-01-30,374,Y,Y,Screening,0,2015-01-22,1,2015-08-21,212,55,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-009,Clinical Site 04,4,39,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-01-22,2015-10-27,279,Y,1,2015-03-21,59,2016-01-30,374,Y,Y,Visit 1,1,2015-03-18,56,2015-08-21,212,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-009,Clinical Site 04,4,39,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-01-22,2015-10-27,279,Y,1,2015-03-21,59,2016-01-30,374,Y,Y,Visit 1,1,2015-03-18,56,2015-08-21,212,53,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-009,Clinical Site 04,4,39,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-01-22,2015-10-27,279,Y,1,2015-03-21,59,2016-01-30,374,Y,Y,Visit 2,2,2015-05-10,109,2015-08-21,212,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-009,Clinical Site 04,4,39,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-01-22,2015-10-27,279,Y,1,2015-03-21,59,2016-01-30,374,Y,Y,Visit 2,2,2015-05-10,109,2015-08-21,212,60,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-009,Clinical Site 04,4,39,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-01-22,2015-10-27,279,Y,1,2015-03-21,59,2016-01-30,374,Y,Y,Visit 3,3,2015-07-09,169,2015-08-21,212,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
04-009,Clinical Site 04,4,39,F,Hispanic,Placebo,PLACEBO,Ongoing,2015-01-22,2015-10-27,279,Y,1,2015-03-21,59,2016-01-30,374,Y,Y,Visit 3,3,2015-07-09,169,2015-08-21,212,43,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-010,Clinical Site 04,4,18,F,White,Treatment B,TRTB,Ongoing,2015-12-14,2016-10-04,296,Y,1,2016-02-11,60,2016-12-14,367,N,Y,Screening,0,2015-12-14,1,2016-04-02,111,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-010,Clinical Site 04,4,18,F,White,Treatment B,TRTB,Ongoing,2015-12-14,2016-10-04,296,Y,1,2016-02-11,60,2016-12-14,367,N,Y,Screening,0,2015-12-14,1,2016-04-02,111,62,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-010,Clinical Site 04,4,18,F,White,Treatment B,TRTB,Ongoing,2015-12-14,2016-10-04,296,Y,1,2016-02-11,60,2016-12-14,367,N,Y,Visit 1,1,2016-02-14,63,2016-04-02,111,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-010,Clinical Site 04,4,18,F,White,Treatment B,TRTB,Ongoing,2015-12-14,2016-10-04,296,Y,1,2016-02-11,60,2016-12-14,367,N,Y,Visit 1,1,2016-02-14,63,2016-04-02,111,48,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-011,Clinical Site 04,4,48,M,Other/Mixed,Treatment B,TRTB,Completed,2015-10-16,2016-10-20,371,Y,1,2015-12-09,55,2016-10-07,358,Y,Y,Screening,0,2015-10-16,1,2016-11-07,389,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-011,Clinical Site 04,4,48,M,Other/Mixed,Treatment B,TRTB,Completed,2015-10-16,2016-10-20,371,Y,1,2015-12-09,55,2016-10-07,358,Y,Y,Screening,0,2015-10-16,1,2016-11-07,389,60,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-011,Clinical Site 04,4,48,M,Other/Mixed,Treatment B,TRTB,Completed,2015-10-16,2016-10-20,371,Y,1,2015-12-09,55,2016-10-07,358,Y,Y,Visit 1,1,2015-12-15,61,2016-11-07,389,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-011,Clinical Site 04,4,48,M,Other/Mixed,Treatment B,TRTB,Completed,2015-10-16,2016-10-20,371,Y,1,2015-12-09,55,2016-10-07,358,Y,Y,Visit 1,1,2015-12-15,61,2016-11-07,389,51,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-011,Clinical Site 04,4,48,M,Other/Mixed,Treatment B,TRTB,Completed,2015-10-16,2016-10-20,371,Y,1,2015-12-09,55,2016-10-07,358,Y,Y,Visit 2,2,2016-02-04,112,2016-11-07,389,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-011,Clinical Site 04,4,48,M,Other/Mixed,Treatment B,TRTB,Completed,2015-10-16,2016-10-20,371,Y,1,2015-12-09,55,2016-10-07,358,Y,Y,Visit 2,2,2016-02-04,112,2016-11-07,389,62,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
04-011,Clinical Site 04,4,48,M,Other/Mixed,Treatment B,TRTB,Completed,2015-10-16,2016-10-20,371,Y,1,2015-12-09,55,2016-10-07,358,Y,Y,Visit 3,3,2016-04-06,174,2016-11-07,389,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-011,Clinical Site 04,4,48,M,Other/Mixed,Treatment B,TRTB,Completed,2015-10-16,2016-10-20,371,Y,1,2015-12-09,55,2016-10-07,358,Y,Y,Visit 3,3,2016-04-06,174,2016-11-07,389,44,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
04-011,Clinical Site 04,4,48,M,Other/Mixed,Treatment B,TRTB,Completed,2015-10-16,2016-10-20,371,Y,1,2015-12-09,55,2016-10-07,358,Y,Y,Visit 4,4,2016-05-20,218,2016-11-07,389,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-011,Clinical Site 04,4,48,M,Other/Mixed,Treatment B,TRTB,Completed,2015-10-16,2016-10-20,371,Y,1,2015-12-09,55,2016-10-07,358,Y,Y,Visit 4,4,2016-05-20,218,2016-11-07,389,63,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-011,Clinical Site 04,4,48,M,Other/Mixed,Treatment B,TRTB,Completed,2015-10-16,2016-10-20,371,Y,1,2015-12-09,55,2016-10-07,358,Y,Y,Visit 5,5,2016-07-22,281,2016-11-07,389,108,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-012,Clinical Site 04,4,33,M,Black,Treatment B,TRTB,Completed,2015-06-26,2016-06-16,357,Y,1,2015-08-23,59,2016-06-20,361,N,N,Screening,0,2015-06-26,1,2016-08-19,421,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-012,Clinical Site 04,4,33,M,Black,Treatment B,TRTB,Completed,2015-06-26,2016-06-16,357,Y,1,2015-08-23,59,2016-06-20,361,N,N,Screening,0,2015-06-26,1,2016-08-19,421,107,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-012,Clinical Site 04,4,33,M,Black,Treatment B,TRTB,Completed,2015-06-26,2016-06-16,357,Y,1,2015-08-23,59,2016-06-20,361,N,N,Visit 2,2,2015-10-11,108,2016-08-19,421,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-012,Clinical Site 04,4,33,M,Black,Treatment B,TRTB,Completed,2015-06-26,2016-06-16,357,Y,1,2015-08-23,59,2016-06-20,361,N,N,Visit 2,2,2015-10-11,108,2016-08-19,421,67,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-012,Clinical Site 04,4,33,M,Black,Treatment B,TRTB,Completed,2015-06-26,2016-06-16,357,Y,1,2015-08-23,59,2016-06-20,361,N,N,Visit 3,3,2015-12-17,175,2016-08-19,421,50,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-012,Clinical Site 04,4,33,M,Black,Treatment B,TRTB,Completed,2015-06-26,2016-06-16,357,Y,1,2015-08-23,59,2016-06-20,361,N,N,Visit 4,4,2016-02-05,225,2016-08-19,421,57,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-012,Clinical Site 04,4,33,M,Black,Treatment B,TRTB,Completed,2015-06-26,2016-06-16,357,Y,1,2015-08-23,59,2016-06-20,361,N,N,Visit 5,5,2016-04-02,282,2016-08-19,421,56,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-012,Clinical Site 04,4,33,M,Black,Treatment B,TRTB,Completed,2015-06-26,2016-06-16,357,Y,1,2015-08-23,59,2016-06-20,361,N,N,Visit 6,6,2016-05-28,338,2016-08-19,421,83,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Screening,0,2015-04-22,1,2016-08-06,473,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Screening,0,2015-04-22,1,2016-08-06,473,60,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 1,1,2015-06-21,61,2016-08-06,473,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 1,1,2015-06-21,61,2016-08-06,473,53,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 2,2,2015-08-13,114,2016-08-06,473,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 2,2,2015-08-13,114,2016-08-06,473,47,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 3,3,2015-09-29,161,2016-08-06,473,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 3,3,2015-09-29,161,2016-08-06,473,68,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 4,4,2015-12-06,229,2016-08-06,473,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 4,4,2015-12-06,229,2016-08-06,473,56,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 5,5,2016-01-31,285,2016-08-06,473,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 5,5,2016-01-31,285,2016-08-06,473,56,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 6,6,2016-03-27,341,2016-08-06,473,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,Visit 6,6,2016-03-27,341,2016-08-06,473,28,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-013,Clinical Site 04,4,19,M,Hispanic,Treatment A,TRTA,Completed,2015-04-22,2016-04-24,369,Y,1,2015-06-18,58,2016-04-28,373,Y,Y,End of Study,7,2016-04-24,369,2016-08-06,473,104,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
04-014,Clinical Site 04,4,36,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-05-14,2015-10-28,168,Y,1,2015-07-06,54,2016-05-20,373,N,Y,Screening,0,2015-05-14,1,2015-08-08,87,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-014,Clinical Site 04,4,36,M,Other/Mixed,Treatment B,TRTB,Ongoing,2015-05-14,2015-10-28,168,Y,1,2015-07-06,54,2016-05-20,373,N,Y,Screening,0,2015-05-14,1,2015-08-08,87,86,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-015,Clinical Site 04,4,40,F,Hispanic,Treatment B,TRTB,Ongoing,2015-11-26,2016-06-08,196,Y,1,2016-01-25,61,2016-11-21,362,N,Y,Screening,0,2015-11-26,1,2016-03-02,98,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-015,Clinical Site 04,4,40,F,Hispanic,Treatment B,TRTB,Ongoing,2015-11-26,2016-06-08,196,Y,1,2016-01-25,61,2016-11-21,362,N,Y,Screening,0,2015-11-26,1,2016-03-02,98,52,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-015,Clinical Site 04,4,40,F,Hispanic,Treatment B,TRTB,Ongoing,2015-11-26,2016-06-08,196,Y,1,2016-01-25,61,2016-11-21,362,N,Y,Visit 1,1,2016-01-17,53,2016-03-02,98,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
04-015,Clinical Site 04,4,40,F,Hispanic,Treatment B,TRTB,Ongoing,2015-11-26,2016-06-08,196,Y,1,2016-01-25,61,2016-11-21,362,N,Y,Visit 1,1,2016-01-17,53,2016-03-02,98,8,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-015,Clinical Site 04,4,40,F,Hispanic,Treatment B,TRTB,Ongoing,2015-11-26,2016-06-08,196,Y,1,2016-01-25,61,2016-11-21,362,N,Y,Unscheduled 1.1,1.1,2016-01-25,61,2016-03-02,98,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-015,Clinical Site 04,4,40,F,Hispanic,Treatment B,TRTB,Ongoing,2015-11-26,2016-06-08,196,Y,1,2016-01-25,61,2016-11-21,362,N,Y,Unscheduled 1.1,1.1,2016-01-25,61,2016-03-02,98,37,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-016,Clinical Site 04,4,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-04-27,2016-03-07,316,Y,1,2015-06-17,52,2016-05-01,371,Y,N,Screening,0,2015-04-27,1,2015-09-11,138,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-016,Clinical Site 04,4,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-04-27,2016-03-07,316,Y,1,2015-06-17,52,2016-05-01,371,Y,N,Screening,0,2015-04-27,1,2015-09-11,138,54,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-016,Clinical Site 04,4,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-04-27,2016-03-07,316,Y,1,2015-06-17,52,2016-05-01,371,Y,N,Visit 1,1,2015-06-20,55,2015-09-11,138,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-016,Clinical Site 04,4,40,M,Hispanic,Treatment A,TRTA,Ongoing,2015-04-27,2016-03-07,316,Y,1,2015-06-17,52,2016-05-01,371,Y,N,Visit 1,1,2015-06-20,55,2015-09-11,138,83,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-019,Clinical Site 04,4,55,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-01-20,2015-07-03,165,Y,1,2015-03-12,52,2016-01-25,371,Y,Y,Screening,0,2015-01-20,1,2015-10-08,262,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-019,Clinical Site 04,4,55,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-01-20,2015-07-03,165,Y,1,2015-03-12,52,2016-01-25,371,Y,Y,Screening,0,2015-01-20,1,2015-10-08,262,62,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-019,Clinical Site 04,4,55,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-01-20,2015-07-03,165,Y,1,2015-03-12,52,2016-01-25,371,Y,Y,Visit 1,1,2015-03-23,63,2015-10-08,262,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
04-019,Clinical Site 04,4,55,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-01-20,2015-07-03,165,Y,1,2015-03-12,52,2016-01-25,371,Y,Y,Visit 1,1,2015-03-23,63,2015-10-08,262,52,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-019,Clinical Site 04,4,55,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-01-20,2015-07-03,165,Y,1,2015-03-12,52,2016-01-25,371,Y,Y,Visit 2,2,2015-05-14,115,2015-10-08,262,46,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-019,Clinical Site 04,4,55,F,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-01-20,2015-07-03,165,Y,1,2015-03-12,52,2016-01-25,371,Y,Y,Visit 3,3,2015-06-29,161,2015-10-08,262,101,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-020,Clinical Site 04,4,24,F,White,Treatment B,TRTB,Ongoing,2015-09-14,2015-10-12,29,Y,1,2015-11-02,50,2016-09-10,363,Y,Y,Screening,0,2015-09-14,1,2015-12-26,104,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-020,Clinical Site 04,4,24,F,White,Treatment B,TRTB,Ongoing,2015-09-14,2015-10-12,29,Y,1,2015-11-02,50,2016-09-10,363,Y,Y,Screening,0,2015-09-14,1,2015-12-26,104,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-020,Clinical Site 04,4,24,F,White,Treatment B,TRTB,Ongoing,2015-09-14,2015-10-12,29,Y,1,2015-11-02,50,2016-09-10,363,Y,Y,Unscheduled 0.1,0.1,2015-09-22,9,2015-12-26,104,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-020,Clinical Site 04,4,24,F,White,Treatment B,TRTB,Ongoing,2015-09-14,2015-10-12,29,Y,1,2015-11-02,50,2016-09-10,363,Y,Y,Unscheduled 0.1,0.1,2015-09-22,9,2015-12-26,104,95,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-021,Clinical Site 04,4,21,M,White,Placebo,PLACEBO,Ongoing,2015-06-20,2015-09-01,74,Y,1,2015-08-20,62,2016-06-22,369,Y,N,Screening,0,2015-06-20,1,2015-07-24,35,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-021,Clinical Site 04,4,21,M,White,Placebo,PLACEBO,Ongoing,2015-06-20,2015-09-01,74,Y,1,2015-08-20,62,2016-06-22,369,Y,N,Screening,0,2015-06-20,1,2015-07-24,35,34,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-022,Clinical Site 04,4,54,F,White,Placebo,PLACEBO,Ongoing,2015-12-26,2016-07-08,196,Y,1,2016-02-20,57,2017-01-01,373,Y,N,Screening,0,2015-12-26,1,2016-06-20,178,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-022,Clinical Site 04,4,54,F,White,Placebo,PLACEBO,Ongoing,2015-12-26,2016-07-08,196,Y,1,2016-02-20,57,2017-01-01,373,Y,N,Screening,0,2015-12-26,1,2016-06-20,178,62,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-022,Clinical Site 04,4,54,F,White,Placebo,PLACEBO,Ongoing,2015-12-26,2016-07-08,196,Y,1,2016-02-20,57,2017-01-01,373,Y,N,Visit 1,1,2016-02-26,63,2016-06-20,178,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-022,Clinical Site 04,4,54,F,White,Placebo,PLACEBO,Ongoing,2015-12-26,2016-07-08,196,Y,1,2016-02-20,57,2017-01-01,373,Y,N,Visit 1,1,2016-02-26,63,2016-06-20,178,8,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-022,Clinical Site 04,4,54,F,White,Placebo,PLACEBO,Ongoing,2015-12-26,2016-07-08,196,Y,1,2016-02-20,57,2017-01-01,373,Y,N,Unscheduled 1.1,1.1,2016-03-05,71,2016-06-20,178,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDu,3,#f4a582
04-022,Clinical Site 04,4,54,F,White,Placebo,PLACEBO,Ongoing,2015-12-26,2016-07-08,196,Y,1,2016-02-20,57,2017-01-01,373,Y,N,Unscheduled 1.1,1.1,2016-03-05,71,2016-06-20,178,107,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-024,Clinical Site 04,4,26,M,Other/Mixed,Placebo,PLACEBO,Completed,2015-05-05,2016-04-24,356,Y,1,2015-06-29,56,2016-05-12,374,Y,N,Screening,0,2015-05-05,1,2016-07-22,445,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-024,Clinical Site 04,4,26,M,Other/Mixed,Placebo,PLACEBO,Completed,2015-05-05,2016-04-24,356,Y,1,2015-06-29,56,2016-05-12,374,Y,N,Screening,0,2015-05-05,1,2016-07-22,445,55,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-024,Clinical Site 04,4,26,M,Other/Mixed,Placebo,PLACEBO,Completed,2015-05-05,2016-04-24,356,Y,1,2015-06-29,56,2016-05-12,374,Y,N,Visit 1,1,2015-06-29,56,2016-07-22,445,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-024,Clinical Site 04,4,26,M,Other/Mixed,Placebo,PLACEBO,Completed,2015-05-05,2016-04-24,356,Y,1,2015-06-29,56,2016-05-12,374,Y,N,Visit 1,1,2015-06-29,56,2016-07-22,445,55,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-024,Clinical Site 04,4,26,M,Other/Mixed,Placebo,PLACEBO,Completed,2015-05-05,2016-04-24,356,Y,1,2015-06-29,56,2016-05-12,374,Y,N,Visit 2,2,2015-08-23,111,2016-07-22,445,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-024,Clinical Site 04,4,26,M,Other/Mixed,Placebo,PLACEBO,Completed,2015-05-05,2016-04-24,356,Y,1,2015-06-29,56,2016-05-12,374,Y,N,Visit 2,2,2015-08-23,111,2016-07-22,445,62,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-024,Clinical Site 04,4,26,M,Other/Mixed,Placebo,PLACEBO,Completed,2015-05-05,2016-04-24,356,Y,1,2015-06-29,56,2016-05-12,374,Y,N,Visit 3,3,2015-10-24,173,2016-07-22,445,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-024,Clinical Site 04,4,26,M,Other/Mixed,Placebo,PLACEBO,Completed,2015-05-05,2016-04-24,356,Y,1,2015-06-29,56,2016-05-12,374,Y,N,Visit 3,3,2015-10-24,173,2016-07-22,445,58,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-024,Clinical Site 04,4,26,M,Other/Mixed,Placebo,PLACEBO,Completed,2015-05-05,2016-04-24,356,Y,1,2015-06-29,56,2016-05-12,374,Y,N,Visit 4,4,2015-12-21,231,2016-07-22,445,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-024,Clinical Site 04,4,26,M,Other/Mixed,Placebo,PLACEBO,Completed,2015-05-05,2016-04-24,356,Y,1,2015-06-29,56,2016-05-12,374,Y,N,Visit 4,4,2015-12-21,231,2016-07-22,445,106,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-024,Clinical Site 04,4,26,M,Other/Mixed,Placebo,PLACEBO,Completed,2015-05-05,2016-04-24,356,Y,1,2015-06-29,56,2016-05-12,374,Y,N,Visit 6,6,2016-04-05,337,2016-07-22,445,108,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-025,Clinical Site 04,4,26,M,Black,Treatment A,TRTA,Ongoing,2015-08-08,2015-09-04,28,Y,1,2015-10-05,59,2016-07-30,358,N,Y,Screening,0,2015-08-08,1,2015-11-22,107,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-025,Clinical Site 04,4,26,M,Black,Treatment A,TRTA,Ongoing,2015-08-08,2015-09-04,28,Y,1,2015-10-05,59,2016-07-30,358,N,Y,Screening,0,2015-08-08,1,2015-11-22,107,106,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-026,Clinical Site 04,4,27,M,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-07-02,2015-07-21,20,Y,1,2015-08-26,56,2016-07-05,370,Y,Y,Screening,0,2015-07-02,1,2015-08-24,54,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-026,Clinical Site 04,4,27,M,Other/Mixed,Placebo,PLACEBO,Ongoing,2015-07-02,2015-07-21,20,Y,1,2015-08-26,56,2016-07-05,370,Y,Y,Screening,0,2015-07-02,1,2015-08-24,54,53,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-027,Clinical Site 04,4,28,M,White,Treatment A,TRTA,Ongoing,2015-01-13,2015-09-10,241,Y,1,2015-03-06,53,2016-01-12,365,N,Y,Screening,0,2015-01-13,1,2015-08-11,211,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-027,Clinical Site 04,4,28,M,White,Treatment A,TRTA,Ongoing,2015-01-13,2015-09-10,241,Y,1,2015-03-06,53,2016-01-12,365,N,Y,Screening,0,2015-01-13,1,2015-08-11,211,52,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-027,Clinical Site 04,4,28,M,White,Treatment A,TRTA,Ongoing,2015-01-13,2015-09-10,241,Y,1,2015-03-06,53,2016-01-12,365,N,Y,Visit 1,1,2015-03-06,53,2015-08-11,211,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-027,Clinical Site 04,4,28,M,White,Treatment A,TRTA,Ongoing,2015-01-13,2015-09-10,241,Y,1,2015-03-06,53,2016-01-12,365,N,Y,Visit 1,1,2015-03-06,53,2015-08-11,211,57,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
04-027,Clinical Site 04,4,28,M,White,Treatment A,TRTA,Ongoing,2015-01-13,2015-09-10,241,Y,1,2015-03-06,53,2016-01-12,365,N,Y,Visit 2,2,2015-05-02,110,2015-08-11,211,59,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-027,Clinical Site 04,4,28,M,White,Treatment A,TRTA,Ongoing,2015-01-13,2015-09-10,241,Y,1,2015-03-06,53,2016-01-12,365,N,Y,Visit 3,3,2015-06-30,169,2015-08-11,211,42,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-028,Clinical Site 04,4,51,M,Black,Placebo,PLACEBO,Ongoing,2015-01-23,2015-12-13,325,Y,1,2015-03-20,57,2016-01-31,374,Y,Y,Screening,0,2015-01-23,1,2015-08-18,208,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-028,Clinical Site 04,4,51,M,Black,Placebo,PLACEBO,Ongoing,2015-01-23,2015-12-13,325,Y,1,2015-03-20,57,2016-01-31,374,Y,Y,Screening,0,2015-01-23,1,2015-08-18,208,56,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-028,Clinical Site 04,4,51,M,Black,Placebo,PLACEBO,Ongoing,2015-01-23,2015-12-13,325,Y,1,2015-03-20,57,2016-01-31,374,Y,Y,Visit 1,1,2015-03-20,57,2015-08-18,208,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-028,Clinical Site 04,4,51,M,Black,Placebo,PLACEBO,Ongoing,2015-01-23,2015-12-13,325,Y,1,2015-03-20,57,2016-01-31,374,Y,Y,Visit 1,1,2015-03-20,57,2015-08-18,208,58,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
04-028,Clinical Site 04,4,51,M,Black,Placebo,PLACEBO,Ongoing,2015-01-23,2015-12-13,325,Y,1,2015-03-20,57,2016-01-31,374,Y,Y,Visit 2,2,2015-05-17,115,2015-08-18,208,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
04-028,Clinical Site 04,4,51,M,Black,Placebo,PLACEBO,Ongoing,2015-01-23,2015-12-13,325,Y,1,2015-03-20,57,2016-01-31,374,Y,Y,Visit 2,2,2015-05-17,115,2015-08-18,208,53,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-028,Clinical Site 04,4,51,M,Black,Placebo,PLACEBO,Ongoing,2015-01-23,2015-12-13,325,Y,1,2015-03-20,57,2016-01-31,374,Y,Y,Visit 3,3,2015-07-09,168,2015-08-18,208,8,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-028,Clinical Site 04,4,51,M,Black,Placebo,PLACEBO,Ongoing,2015-01-23,2015-12-13,325,Y,1,2015-03-20,57,2016-01-31,374,Y,Y,Unscheduled 3.1,3.1,2015-07-17,176,2015-08-18,208,32,RECIST 1.1,Best Overall Response (RECIST 1.1),NE,4,#969696
04-029,Clinical Site 04,4,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-05-12,2015-12-15,218,Y,1,2015-07-11,61,2016-05-17,372,Y,Y,Screening,0,2015-05-12,1,2015-09-29,141,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
04-029,Clinical Site 04,4,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-05-12,2015-12-15,218,Y,1,2015-07-11,61,2016-05-17,372,Y,Y,Screening,0,2015-05-12,1,2015-09-29,141,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
04-029,Clinical Site 04,4,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-05-12,2015-12-15,218,Y,1,2015-07-11,61,2016-05-17,372,Y,Y,Unscheduled 0.1,0.1,2015-05-20,9,2015-09-29,141,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-029,Clinical Site 04,4,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-05-12,2015-12-15,218,Y,1,2015-07-11,61,2016-05-17,372,Y,Y,Unscheduled 0.1,0.1,2015-05-20,9,2015-09-29,141,7,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
04-029,Clinical Site 04,4,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-05-12,2015-12-15,218,Y,1,2015-07-11,61,2016-05-17,372,Y,Y,Unscheduled 0.2,0.2,2015-05-27,16,2015-09-29,141,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-029,Clinical Site 04,4,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-05-12,2015-12-15,218,Y,1,2015-07-11,61,2016-05-17,372,Y,Y,Unscheduled 0.2,0.2,2015-05-27,16,2015-09-29,141,37,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
04-029,Clinical Site 04,4,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-05-12,2015-12-15,218,Y,1,2015-07-11,61,2016-05-17,372,Y,Y,Visit 1,1,2015-07-03,53,2015-09-29,141,8,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
04-029,Clinical Site 04,4,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-05-12,2015-12-15,218,Y,1,2015-07-11,61,2016-05-17,372,Y,Y,Unscheduled 1.1,1.1,2015-07-11,61,2015-09-29,141,80,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-002,Clinical Site 05,5,24,M,Black,Treatment B,TRTB,Ongoing,2015-10-26,2016-07-22,271,Y,1,2015-12-13,49,2016-10-28,369,N,Y,Screening,0,2015-10-26,1,2016-07-16,265,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-002,Clinical Site 05,5,24,M,Black,Treatment B,TRTB,Ongoing,2015-10-26,2016-07-22,271,Y,1,2015-12-13,49,2016-10-28,369,N,Y,Screening,0,2015-10-26,1,2016-07-16,265,52,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-002,Clinical Site 05,5,24,M,Black,Treatment B,TRTB,Ongoing,2015-10-26,2016-07-22,271,Y,1,2015-12-13,49,2016-10-28,369,N,Y,Visit 1,1,2015-12-17,53,2016-07-16,265,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
05-002,Clinical Site 05,5,24,M,Black,Treatment B,TRTB,Ongoing,2015-10-26,2016-07-22,271,Y,1,2015-12-13,49,2016-10-28,369,N,Y,Visit 1,1,2015-12-17,53,2016-07-16,265,59,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-002,Clinical Site 05,5,24,M,Black,Treatment B,TRTB,Ongoing,2015-10-26,2016-07-22,271,Y,1,2015-12-13,49,2016-10-28,369,N,Y,Visit 2,2,2016-02-14,112,2016-07-16,265,58,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-002,Clinical Site 05,5,24,M,Black,Treatment B,TRTB,Ongoing,2015-10-26,2016-07-22,271,Y,1,2015-12-13,49,2016-10-28,369,N,Y,Visit 3,3,2016-04-12,170,2016-07-16,265,95,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Screening,0,2015-09-26,1,2016-12-10,442,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Screening,0,2015-09-26,1,2016-12-10,442,56,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Visit 1,1,2015-11-21,57,2016-12-10,442,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Visit 1,1,2015-11-21,57,2016-12-10,442,59,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Visit 2,2,2016-01-19,116,2016-12-10,442,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Visit 2,2,2016-01-19,116,2016-12-10,442,112,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Visit 4,4,2016-05-10,228,2016-12-10,442,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Visit 4,4,2016-05-10,228,2016-12-10,442,56,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Visit 5,5,2016-07-05,284,2016-12-10,442,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Visit 5,5,2016-07-05,284,2016-12-10,442,8,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Unscheduled 5.1,5.1,2016-07-13,292,2016-12-10,442,37,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Visit 6,6,2016-08-19,329,2016-12-10,442,8,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-003,Clinical Site 05,5,42,M,Black,Treatment B,TRTB,Completed,2015-09-26,2016-09-25,366,Y,1,2015-11-18,54,2016-09-20,361,Y,N,Unscheduled 6.1,6.1,2016-08-27,337,2016-12-10,442,105,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
05-004,Clinical Site 05,5,47,M,White,Placebo,PLACEBO,Ongoing,2015-10-29,2015-11-29,32,Y,1,2015-12-22,55,2016-10-26,364,Y,N,Screening,0,2015-10-29,1,2015-12-03,36,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-004,Clinical Site 05,5,47,M,White,Placebo,PLACEBO,Ongoing,2015-10-29,2015-11-29,32,Y,1,2015-12-22,55,2016-10-26,364,Y,N,Screening,0,2015-10-29,1,2015-12-03,36,35,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-007,Clinical Site 05,5,43,M,White,Treatment B,TRTB,Ongoing,2015-07-07,2015-08-17,42,Y,1,2015-08-31,56,2016-07-15,375,Y,Y,Screening,0,2015-07-07,1,2015-10-27,113,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-007,Clinical Site 05,5,43,M,White,Treatment B,TRTB,Ongoing,2015-07-07,2015-08-17,42,Y,1,2015-08-31,56,2016-07-15,375,Y,Y,Screening,0,2015-07-07,1,2015-10-27,113,112,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-008,Clinical Site 05,5,26,F,Hispanic,Treatment B,TRTB,Ongoing,2015-10-12,2016-10-04,359,Y,1,2015-11-29,49,2016-10-19,374,Y,Y,Screening,0,2015-10-12,1,2016-12-25,441,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-008,Clinical Site 05,5,26,F,Hispanic,Treatment B,TRTB,Ongoing,2015-10-12,2016-10-04,359,Y,1,2015-11-29,49,2016-10-19,374,Y,Y,Screening,0,2015-10-12,1,2016-12-25,441,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-008,Clinical Site 05,5,26,F,Hispanic,Treatment B,TRTB,Ongoing,2015-10-12,2016-10-04,359,Y,1,2015-11-29,49,2016-10-19,374,Y,Y,Unscheduled 0.1,0.1,2015-10-20,9,2016-12-25,441,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
05-008,Clinical Site 05,5,26,F,Hispanic,Treatment B,TRTB,Ongoing,2015-10-12,2016-10-04,359,Y,1,2015-11-29,49,2016-10-19,374,Y,Y,Unscheduled 0.1,0.1,2015-10-20,9,2016-12-25,441,53,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-008,Clinical Site 05,5,26,F,Hispanic,Treatment B,TRTB,Ongoing,2015-10-12,2016-10-04,359,Y,1,2015-11-29,49,2016-10-19,374,Y,Y,Visit 1,1,2015-12-12,62,2016-12-25,441,8,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-008,Clinical Site 05,5,26,F,Hispanic,Treatment B,TRTB,Ongoing,2015-10-12,2016-10-04,359,Y,1,2015-11-29,49,2016-10-19,374,Y,Y,Unscheduled 1.1,1.1,2015-12-20,70,2016-12-25,441,42,RECIST 1.1,Best Overall Response (RECIST 1.1),NE,4,#969696
05-008,Clinical Site 05,5,26,F,Hispanic,Treatment B,TRTB,Ongoing,2015-10-12,2016-10-04,359,Y,1,2015-11-29,49,2016-10-19,374,Y,Y,Visit 2,2,2016-01-31,112,2016-12-25,441,52,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
05-008,Clinical Site 05,5,26,F,Hispanic,Treatment B,TRTB,Ongoing,2015-10-12,2016-10-04,359,Y,1,2015-11-29,49,2016-10-19,374,Y,Y,Visit 3,3,2016-03-23,164,2016-12-25,441,177,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-008,Clinical Site 05,5,26,F,Hispanic,Treatment B,TRTB,Ongoing,2015-10-12,2016-10-04,359,Y,1,2015-11-29,49,2016-10-19,374,Y,Y,Visit 6,6,2016-09-16,341,2016-12-25,441,100,RECIST 1.1,Best Overall Response (RECIST 1.1),NE,4,#969696
05-009,Clinical Site 05,5,42,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-16,2016-12-24,375,Y,1,2016-02-06,53,2016-12-13,364,Y,Y,Screening,0,2015-12-16,1,2016-08-20,249,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-009,Clinical Site 05,5,42,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-16,2016-12-24,375,Y,1,2016-02-06,53,2016-12-13,364,Y,Y,Screening,0,2015-12-16,1,2016-08-20,249,56,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-009,Clinical Site 05,5,42,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-16,2016-12-24,375,Y,1,2016-02-06,53,2016-12-13,364,Y,Y,Visit 1,1,2016-02-10,57,2016-08-20,249,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-009,Clinical Site 05,5,42,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-16,2016-12-24,375,Y,1,2016-02-06,53,2016-12-13,364,Y,Y,Visit 1,1,2016-02-10,57,2016-08-20,249,50,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-009,Clinical Site 05,5,42,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-16,2016-12-24,375,Y,1,2016-02-06,53,2016-12-13,364,Y,Y,Visit 2,2,2016-03-31,107,2016-08-20,249,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-009,Clinical Site 05,5,42,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-16,2016-12-24,375,Y,1,2016-02-06,53,2016-12-13,364,Y,Y,Visit 2,2,2016-03-31,107,2016-08-20,249,67,RECIST 1.1,Best Overall Response (RECIST 1.1),NE,4,#969696
05-009,Clinical Site 05,5,42,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-16,2016-12-24,375,Y,1,2016-02-06,53,2016-12-13,364,Y,Y,Visit 3,3,2016-06-06,174,2016-08-20,249,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-009,Clinical Site 05,5,42,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-16,2016-12-24,375,Y,1,2016-02-06,53,2016-12-13,364,Y,Y,Visit 3,3,2016-06-06,174,2016-08-20,249,46,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-009,Clinical Site 05,5,42,F,Hispanic,Placebo,PLACEBO,Completed,2015-12-16,2016-12-24,375,Y,1,2016-02-06,53,2016-12-13,364,Y,Y,Visit 4,4,2016-07-22,220,2016-08-20,249,29,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,Screening,0,2015-02-06,1,2016-03-12,401,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,Screening,0,2015-02-06,1,2016-03-12,401,58,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,Visit 1,1,2015-04-05,59,2016-03-12,401,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,Visit 1,1,2015-04-05,59,2016-03-12,401,58,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,Visit 2,2,2015-06-02,117,2016-03-12,401,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,Visit 2,2,2015-06-02,117,2016-03-12,401,49,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,Visit 3,3,2015-07-21,166,2016-03-12,401,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,Visit 3,3,2015-07-21,166,2016-03-12,401,55,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,Visit 4,4,2015-09-14,221,2016-03-12,401,55,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,Visit 5,5,2015-11-08,276,2016-03-12,401,59,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,Visit 6,6,2016-01-06,335,2016-03-12,401,30,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-010,Clinical Site 05,5,43,F,White,Treatment B,TRTB,Completed,2015-02-06,2016-02-06,366,Y,1,2015-04-01,55,2016-02-15,375,Y,Y,End of Study,7,2016-02-05,365,2016-03-12,401,36,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-011,Clinical Site 05,5,49,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-02-04,2015-06-25,142,Y,1,2015-04-01,57,2016-02-04,366,Y,Y,Screening,0,2015-02-04,1,2015-06-19,136,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-011,Clinical Site 05,5,49,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-02-04,2015-06-25,142,Y,1,2015-04-01,57,2016-02-04,366,Y,Y,Screening,0,2015-02-04,1,2015-06-19,136,62,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-011,Clinical Site 05,5,49,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-02-04,2015-06-25,142,Y,1,2015-04-01,57,2016-02-04,366,Y,Y,Visit 1,1,2015-04-07,63,2015-06-19,136,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-011,Clinical Site 05,5,49,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-02-04,2015-06-25,142,Y,1,2015-04-01,57,2016-02-04,366,Y,Y,Visit 1,1,2015-04-07,63,2015-06-19,136,73,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-012,Clinical Site 05,5,45,M,Black,Treatment A,TRTA,Completed,2015-04-18,2016-04-26,375,Y,1,2015-06-11,55,2016-04-16,365,Y,Y,Screening,0,2015-04-18,1,2016-05-02,381,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-012,Clinical Site 05,5,45,M,Black,Treatment A,TRTA,Completed,2015-04-18,2016-04-26,375,Y,1,2015-06-11,55,2016-04-16,365,Y,Y,Screening,0,2015-04-18,1,2016-05-02,381,48,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-012,Clinical Site 05,5,45,M,Black,Treatment A,TRTA,Completed,2015-04-18,2016-04-26,375,Y,1,2015-06-11,55,2016-04-16,365,Y,Y,Visit 1,1,2015-06-05,49,2016-05-02,381,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-012,Clinical Site 05,5,45,M,Black,Treatment A,TRTA,Completed,2015-04-18,2016-04-26,375,Y,1,2015-06-11,55,2016-04-16,365,Y,Y,Visit 1,1,2015-06-05,49,2016-05-02,381,67,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
05-012,Clinical Site 05,5,45,M,Black,Treatment A,TRTA,Completed,2015-04-18,2016-04-26,375,Y,1,2015-06-11,55,2016-04-16,365,Y,Y,Visit 2,2,2015-08-11,116,2016-05-02,381,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-012,Clinical Site 05,5,45,M,Black,Treatment A,TRTA,Completed,2015-04-18,2016-04-26,375,Y,1,2015-06-11,55,2016-04-16,365,Y,Y,Visit 2,2,2015-08-11,116,2016-05-02,381,45,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-012,Clinical Site 05,5,45,M,Black,Treatment A,TRTA,Completed,2015-04-18,2016-04-26,375,Y,1,2015-06-11,55,2016-04-16,365,Y,Y,Visit 3,3,2015-09-25,161,2016-05-02,381,66,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
05-012,Clinical Site 05,5,45,M,Black,Treatment A,TRTA,Completed,2015-04-18,2016-04-26,375,Y,1,2015-06-11,55,2016-04-16,365,Y,Y,Visit 4,4,2015-11-30,227,2016-05-02,381,47,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-012,Clinical Site 05,5,45,M,Black,Treatment A,TRTA,Completed,2015-04-18,2016-04-26,375,Y,1,2015-06-11,55,2016-04-16,365,Y,Y,Visit 5,5,2016-01-16,274,2016-05-02,381,65,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-012,Clinical Site 05,5,45,M,Black,Treatment A,TRTA,Completed,2015-04-18,2016-04-26,375,Y,1,2015-06-11,55,2016-04-16,365,Y,Y,Visit 6,6,2016-03-21,339,2016-05-02,381,42,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-013,Clinical Site 05,5,39,M,Hispanic,Treatment A,TRTA,Completed,2015-10-22,2016-10-22,367,Y,1,2015-12-21,61,2016-10-18,363,Y,Y,Screening,0,2015-10-22,1,2016-05-09,201,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-013,Clinical Site 05,5,39,M,Hispanic,Treatment A,TRTA,Completed,2015-10-22,2016-10-22,367,Y,1,2015-12-21,61,2016-10-18,363,Y,Y,Screening,0,2015-10-22,1,2016-05-09,201,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-013,Clinical Site 05,5,39,M,Hispanic,Treatment A,TRTA,Completed,2015-10-22,2016-10-22,367,Y,1,2015-12-21,61,2016-10-18,363,Y,Y,Unscheduled 0.1,0.1,2015-10-30,9,2016-05-09,201,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
05-013,Clinical Site 05,5,39,M,Hispanic,Treatment A,TRTA,Completed,2015-10-22,2016-10-22,367,Y,1,2015-12-21,61,2016-10-18,363,Y,Y,Unscheduled 0.1,0.1,2015-10-30,9,2016-05-09,201,46,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-013,Clinical Site 05,5,39,M,Hispanic,Treatment A,TRTA,Completed,2015-10-22,2016-10-22,367,Y,1,2015-12-21,61,2016-10-18,363,Y,Y,Visit 1,1,2015-12-15,55,2016-05-09,201,55,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-013,Clinical Site 05,5,39,M,Hispanic,Treatment A,TRTA,Completed,2015-10-22,2016-10-22,367,Y,1,2015-12-21,61,2016-10-18,363,Y,Y,Visit 2,2,2016-02-08,110,2016-05-09,201,57,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-013,Clinical Site 05,5,39,M,Hispanic,Treatment A,TRTA,Completed,2015-10-22,2016-10-22,367,Y,1,2015-12-21,61,2016-10-18,363,Y,Y,Visit 3,3,2016-04-05,167,2016-05-09,201,34,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-014,Clinical Site 05,5,32,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-07-01,2016-03-14,258,Y,1,2015-08-30,61,2016-07-07,373,Y,Y,Screening,0,2015-07-01,1,2016-02-05,220,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-014,Clinical Site 05,5,32,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-07-01,2016-03-14,258,Y,1,2015-08-30,61,2016-07-07,373,Y,Y,Screening,0,2015-07-01,1,2016-02-05,220,105,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-014,Clinical Site 05,5,32,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-07-01,2016-03-14,258,Y,1,2015-08-30,61,2016-07-07,373,Y,Y,Visit 2,2,2015-10-14,106,2016-02-05,220,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
05-014,Clinical Site 05,5,32,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-07-01,2016-03-14,258,Y,1,2015-08-30,61,2016-07-07,373,Y,Y,Visit 2,2,2015-10-14,106,2016-02-05,220,62,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-014,Clinical Site 05,5,32,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-07-01,2016-03-14,258,Y,1,2015-08-30,61,2016-07-07,373,Y,Y,Visit 3,3,2015-12-15,168,2016-02-05,220,52,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-015,Clinical Site 05,5,38,F,Hispanic,Treatment B,TRTB,Ongoing,2015-01-11,2015-11-14,308,Y,1,2015-03-11,60,2016-01-05,360,Y,Y,Screening,0,2015-01-11,1,2015-11-04,298,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-015,Clinical Site 05,5,38,F,Hispanic,Treatment B,TRTB,Ongoing,2015-01-11,2015-11-14,308,Y,1,2015-03-11,60,2016-01-05,360,Y,Y,Screening,0,2015-01-11,1,2015-11-04,298,55,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-015,Clinical Site 05,5,38,F,Hispanic,Treatment B,TRTB,Ongoing,2015-01-11,2015-11-14,308,Y,1,2015-03-11,60,2016-01-05,360,Y,Y,Visit 1,1,2015-03-07,56,2015-11-04,298,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-015,Clinical Site 05,5,38,F,Hispanic,Treatment B,TRTB,Ongoing,2015-01-11,2015-11-14,308,Y,1,2015-03-11,60,2016-01-05,360,Y,Y,Visit 1,1,2015-03-07,56,2015-11-04,298,52,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-015,Clinical Site 05,5,38,F,Hispanic,Treatment B,TRTB,Ongoing,2015-01-11,2015-11-14,308,Y,1,2015-03-11,60,2016-01-05,360,Y,Y,Visit 2,2,2015-04-28,108,2015-11-04,298,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-015,Clinical Site 05,5,38,F,Hispanic,Treatment B,TRTB,Ongoing,2015-01-11,2015-11-14,308,Y,1,2015-03-11,60,2016-01-05,360,Y,Y,Visit 2,2,2015-04-28,108,2015-11-04,298,113,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-015,Clinical Site 05,5,38,F,Hispanic,Treatment B,TRTB,Ongoing,2015-01-11,2015-11-14,308,Y,1,2015-03-11,60,2016-01-05,360,Y,Y,Visit 4,4,2015-08-19,221,2015-11-04,298,77,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-016,Clinical Site 05,5,42,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-06-15,2015-07-31,47,Y,1,2015-08-10,57,2016-06-14,366,Y,Y,Screening,0,2015-06-15,1,2015-08-13,60,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-016,Clinical Site 05,5,42,F,Other/Mixed,Treatment A,TRTA,Ongoing,2015-06-15,2015-07-31,47,Y,1,2015-08-10,57,2016-06-14,366,Y,Y,Screening,0,2015-06-15,1,2015-08-13,60,59,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-017,Clinical Site 05,5,40,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-07-03,2016-05-10,313,Y,1,2015-08-27,56,2016-06-26,360,Y,Y,Screening,0,2015-07-03,1,2016-05-24,327,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-017,Clinical Site 05,5,40,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-07-03,2016-05-10,313,Y,1,2015-08-27,56,2016-06-26,360,Y,Y,Screening,0,2015-07-03,1,2016-05-24,327,56,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-017,Clinical Site 05,5,40,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-07-03,2016-05-10,313,Y,1,2015-08-27,56,2016-06-26,360,Y,Y,Visit 1,1,2015-08-28,57,2016-05-24,327,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-017,Clinical Site 05,5,40,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-07-03,2016-05-10,313,Y,1,2015-08-27,56,2016-06-26,360,Y,Y,Visit 1,1,2015-08-28,57,2016-05-24,327,8,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-017,Clinical Site 05,5,40,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-07-03,2016-05-10,313,Y,1,2015-08-27,56,2016-06-26,360,Y,Y,Unscheduled 1.1,1.1,2015-09-05,65,2016-05-24,327,43,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-017,Clinical Site 05,5,40,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-07-03,2016-05-10,313,Y,1,2015-08-27,56,2016-06-26,360,Y,Y,Visit 2,2,2015-10-18,108,2016-05-24,327,56,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-017,Clinical Site 05,5,40,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-07-03,2016-05-10,313,Y,1,2015-08-27,56,2016-06-26,360,Y,Y,Visit 3,3,2015-12-13,164,2016-05-24,327,67,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-017,Clinical Site 05,5,40,M,Hispanic,Placebo,PLACEBO,Ongoing,2015-07-03,2016-05-10,313,Y,1,2015-08-27,56,2016-06-26,360,Y,Y,Visit 4,4,2016-02-18,231,2016-05-24,327,96,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-018,Clinical Site 05,5,36,F,White,Treatment A,TRTA,Ongoing,2015-12-14,2016-09-12,274,Y,1,2016-02-09,58,2016-12-04,357,Y,N,Screening,0,2015-12-14,1,2016-07-20,220,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-018,Clinical Site 05,5,36,F,White,Treatment A,TRTA,Ongoing,2015-12-14,2016-09-12,274,Y,1,2016-02-09,58,2016-12-04,357,Y,N,Screening,0,2015-12-14,1,2016-07-20,220,51,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-018,Clinical Site 05,5,36,F,White,Treatment A,TRTA,Ongoing,2015-12-14,2016-09-12,274,Y,1,2016-02-09,58,2016-12-04,357,Y,N,Visit 1,1,2016-02-03,52,2016-07-20,220,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NE,2,#969696
05-018,Clinical Site 05,5,36,F,White,Treatment A,TRTA,Ongoing,2015-12-14,2016-09-12,274,Y,1,2016-02-09,58,2016-12-04,357,Y,N,Visit 1,1,2016-02-03,52,2016-07-20,220,58,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-018,Clinical Site 05,5,36,F,White,Treatment A,TRTA,Ongoing,2015-12-14,2016-09-12,274,Y,1,2016-02-09,58,2016-12-04,357,Y,N,Visit 2,2,2016-04-01,110,2016-07-20,220,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-018,Clinical Site 05,5,36,F,White,Treatment A,TRTA,Ongoing,2015-12-14,2016-09-12,274,Y,1,2016-02-09,58,2016-12-04,357,Y,N,Visit 2,2,2016-04-01,110,2016-07-20,220,57,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-018,Clinical Site 05,5,36,F,White,Treatment A,TRTA,Ongoing,2015-12-14,2016-09-12,274,Y,1,2016-02-09,58,2016-12-04,357,Y,N,Visit 3,3,2016-05-28,167,2016-07-20,220,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-018,Clinical Site 05,5,36,F,White,Treatment A,TRTA,Ongoing,2015-12-14,2016-09-12,274,Y,1,2016-02-09,58,2016-12-04,357,Y,N,Visit 3,3,2016-05-28,167,2016-07-20,220,53,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
05-019,Clinical Site 05,5,42,F,Black,Placebo,PLACEBO,Ongoing,2015-05-13,2016-03-11,304,Y,1,2015-07-14,63,2016-05-05,359,Y,N,Screening,0,2015-05-13,1,2015-12-07,209,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-019,Clinical Site 05,5,42,F,Black,Placebo,PLACEBO,Ongoing,2015-05-13,2016-03-11,304,Y,1,2015-07-14,63,2016-05-05,359,Y,N,Screening,0,2015-05-13,1,2015-12-07,209,54,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-019,Clinical Site 05,5,42,F,Black,Placebo,PLACEBO,Ongoing,2015-05-13,2016-03-11,304,Y,1,2015-07-14,63,2016-05-05,359,Y,N,Visit 1,1,2015-07-06,55,2015-12-07,209,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-019,Clinical Site 05,5,42,F,Black,Placebo,PLACEBO,Ongoing,2015-05-13,2016-03-11,304,Y,1,2015-07-14,63,2016-05-05,359,Y,N,Visit 1,1,2015-07-06,55,2015-12-07,209,54,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-019,Clinical Site 05,5,42,F,Black,Placebo,PLACEBO,Ongoing,2015-05-13,2016-03-11,304,Y,1,2015-07-14,63,2016-05-05,359,Y,N,Visit 2,2,2015-08-29,109,2015-12-07,209,58,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-019,Clinical Site 05,5,42,F,Black,Placebo,PLACEBO,Ongoing,2015-05-13,2016-03-11,304,Y,1,2015-07-14,63,2016-05-05,359,Y,N,Visit 3,3,2015-10-26,167,2015-12-07,209,42,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-020,Clinical Site 05,5,32,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-21,2015-09-22,155,Y,1,2015-06-13,54,2016-04-15,361,Y,Y,Screening,0,2015-04-21,1,2015-10-23,186,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-020,Clinical Site 05,5,32,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-21,2015-09-22,155,Y,1,2015-06-13,54,2016-04-15,361,Y,Y,Screening,0,2015-04-21,1,2015-10-23,186,51,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-020,Clinical Site 05,5,32,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-21,2015-09-22,155,Y,1,2015-06-13,54,2016-04-15,361,Y,Y,Visit 1,1,2015-06-11,52,2015-10-23,186,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
05-020,Clinical Site 05,5,32,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-21,2015-09-22,155,Y,1,2015-06-13,54,2016-04-15,361,Y,Y,Visit 1,1,2015-06-11,52,2015-10-23,186,8,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-020,Clinical Site 05,5,32,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-21,2015-09-22,155,Y,1,2015-06-13,54,2016-04-15,361,Y,Y,Unscheduled 1.1,1.1,2015-06-19,60,2015-10-23,186,54,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-020,Clinical Site 05,5,32,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-04-21,2015-09-22,155,Y,1,2015-06-13,54,2016-04-15,361,Y,Y,Visit 2,2,2015-08-12,114,2015-10-23,186,72,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-021,Clinical Site 05,5,46,M,Other/Mixed,Treatment A,TRTA,Completed,2015-01-20,2016-01-14,360,Y,1,2015-03-18,58,2016-01-21,367,Y,Y,Screening,0,2015-01-20,1,2015-06-25,157,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-021,Clinical Site 05,5,46,M,Other/Mixed,Treatment A,TRTA,Completed,2015-01-20,2016-01-14,360,Y,1,2015-03-18,58,2016-01-21,367,Y,Y,Screening,0,2015-01-20,1,2015-06-25,157,53,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-021,Clinical Site 05,5,46,M,Other/Mixed,Treatment A,TRTA,Completed,2015-01-20,2016-01-14,360,Y,1,2015-03-18,58,2016-01-21,367,Y,Y,Visit 1,1,2015-03-14,54,2015-06-25,157,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-021,Clinical Site 05,5,46,M,Other/Mixed,Treatment A,TRTA,Completed,2015-01-20,2016-01-14,360,Y,1,2015-03-18,58,2016-01-21,367,Y,Y,Visit 1,1,2015-03-14,54,2015-06-25,157,63,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-021,Clinical Site 05,5,46,M,Other/Mixed,Treatment A,TRTA,Completed,2015-01-20,2016-01-14,360,Y,1,2015-03-18,58,2016-01-21,367,Y,Y,Visit 2,2,2015-05-16,117,2015-06-25,157,40,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
05-022,Clinical Site 05,5,29,F,Black,Placebo,PLACEBO,Ongoing,2015-01-10,2015-08-16,219,Y,1,2015-03-05,55,2016-01-15,371,N,N,Screening,0,2015-01-10,1,2015-07-11,183,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-022,Clinical Site 05,5,29,F,Black,Placebo,PLACEBO,Ongoing,2015-01-10,2015-08-16,219,Y,1,2015-03-05,55,2016-01-15,371,N,N,Screening,0,2015-01-10,1,2015-07-11,183,62,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-022,Clinical Site 05,5,29,F,Black,Placebo,PLACEBO,Ongoing,2015-01-10,2015-08-16,219,Y,1,2015-03-05,55,2016-01-15,371,N,N,Visit 1,1,2015-03-13,63,2015-07-11,183,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-022,Clinical Site 05,5,29,F,Black,Placebo,PLACEBO,Ongoing,2015-01-10,2015-08-16,219,Y,1,2015-03-05,55,2016-01-15,371,N,N,Visit 1,1,2015-03-13,63,2015-07-11,183,48,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-022,Clinical Site 05,5,29,F,Black,Placebo,PLACEBO,Ongoing,2015-01-10,2015-08-16,219,Y,1,2015-03-05,55,2016-01-15,371,N,N,Visit 2,2,2015-04-30,111,2015-07-11,183,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-022,Clinical Site 05,5,29,F,Black,Placebo,PLACEBO,Ongoing,2015-01-10,2015-08-16,219,Y,1,2015-03-05,55,2016-01-15,371,N,N,Visit 2,2,2015-04-30,111,2015-07-11,183,72,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-023,Clinical Site 05,5,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-08-15,2016-05-10,270,Y,1,2015-10-10,57,2016-08-04,356,Y,N,Screening,0,2015-08-15,1,2016-06-11,302,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-023,Clinical Site 05,5,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-08-15,2016-05-10,270,Y,1,2015-10-10,57,2016-08-04,356,Y,N,Screening,0,2015-08-15,1,2016-06-11,302,110,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-023,Clinical Site 05,5,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-08-15,2016-05-10,270,Y,1,2015-10-10,57,2016-08-04,356,Y,N,Visit 2,2,2015-12-03,111,2016-06-11,302,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-023,Clinical Site 05,5,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-08-15,2016-05-10,270,Y,1,2015-10-10,57,2016-08-04,356,Y,N,Visit 2,2,2015-12-03,111,2016-06-11,302,59,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-023,Clinical Site 05,5,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-08-15,2016-05-10,270,Y,1,2015-10-10,57,2016-08-04,356,Y,N,Visit 3,3,2016-01-31,170,2016-06-11,302,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-023,Clinical Site 05,5,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-08-15,2016-05-10,270,Y,1,2015-10-10,57,2016-08-04,356,Y,N,Visit 3,3,2016-01-31,170,2016-06-11,302,58,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-023,Clinical Site 05,5,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-08-15,2016-05-10,270,Y,1,2015-10-10,57,2016-08-04,356,Y,N,Visit 4,4,2016-03-29,228,2016-06-11,302,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-023,Clinical Site 05,5,49,M,Hispanic,Treatment A,TRTA,Ongoing,2015-08-15,2016-05-10,270,Y,1,2015-10-10,57,2016-08-04,356,Y,N,Visit 4,4,2016-03-29,228,2016-06-11,302,74,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-024,Clinical Site 05,5,54,M,White,Treatment A,TRTA,Ongoing,2015-11-17,2016-04-15,151,Y,1,2016-01-07,52,2016-11-16,366,Y,Y,Screening,0,2015-11-17,1,2016-01-26,71,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-024,Clinical Site 05,5,54,M,White,Treatment A,TRTA,Ongoing,2015-11-17,2016-04-15,151,Y,1,2016-01-07,52,2016-11-16,366,Y,Y,Screening,0,2015-11-17,1,2016-01-26,71,70,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-025,Clinical Site 05,5,54,M,White,Treatment A,TRTA,Ongoing,2015-02-28,2015-06-13,106,Y,1,2015-04-23,55,2016-02-20,358,Y,Y,Screening,0,2015-02-28,1,2015-07-13,136,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-025,Clinical Site 05,5,54,M,White,Treatment A,TRTA,Ongoing,2015-02-28,2015-06-13,106,Y,1,2015-04-23,55,2016-02-20,358,Y,Y,Screening,0,2015-02-28,1,2015-07-13,136,8,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-025,Clinical Site 05,5,54,M,White,Treatment A,TRTA,Ongoing,2015-02-28,2015-06-13,106,Y,1,2015-04-23,55,2016-02-20,358,Y,Y,Unscheduled 0.1,0.1,2015-03-08,9,2015-07-13,136,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
05-025,Clinical Site 05,5,54,M,White,Treatment A,TRTA,Ongoing,2015-02-28,2015-06-13,106,Y,1,2015-04-23,55,2016-02-20,358,Y,Y,Unscheduled 0.1,0.1,2015-03-08,9,2015-07-13,136,7,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-025,Clinical Site 05,5,54,M,White,Treatment A,TRTA,Ongoing,2015-02-28,2015-06-13,106,Y,1,2015-04-23,55,2016-02-20,358,Y,Y,Unscheduled 0.2,0.2,2015-03-15,16,2015-07-13,136,45,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-025,Clinical Site 05,5,54,M,White,Treatment A,TRTA,Ongoing,2015-02-28,2015-06-13,106,Y,1,2015-04-23,55,2016-02-20,358,Y,Y,Visit 1,1,2015-04-29,61,2015-07-13,136,75,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-026,Clinical Site 05,5,32,M,Black,Placebo,PLACEBO,Ongoing,2015-01-26,2015-10-20,268,Y,1,2015-03-22,56,2016-02-03,374,Y,N,Screening,0,2015-01-26,1,2015-09-13,231,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-026,Clinical Site 05,5,32,M,Black,Placebo,PLACEBO,Ongoing,2015-01-26,2015-10-20,268,Y,1,2015-03-22,56,2016-02-03,374,Y,N,Screening,0,2015-01-26,1,2015-09-13,231,56,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-026,Clinical Site 05,5,32,M,Black,Placebo,PLACEBO,Ongoing,2015-01-26,2015-10-20,268,Y,1,2015-03-22,56,2016-02-03,374,Y,N,Visit 1,1,2015-03-23,57,2015-09-13,231,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),PDc,4,#b2182b
05-026,Clinical Site 05,5,32,M,Black,Placebo,PLACEBO,Ongoing,2015-01-26,2015-10-20,268,Y,1,2015-03-22,56,2016-02-03,374,Y,N,Visit 1,1,2015-03-23,57,2015-09-13,231,53,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-026,Clinical Site 05,5,32,M,Black,Placebo,PLACEBO,Ongoing,2015-01-26,2015-10-20,268,Y,1,2015-03-22,56,2016-02-03,374,Y,N,Visit 2,2,2015-05-15,110,2015-09-13,231,61,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-026,Clinical Site 05,5,32,M,Black,Placebo,PLACEBO,Ongoing,2015-01-26,2015-10-20,268,Y,1,2015-03-22,56,2016-02-03,374,Y,N,Visit 3,3,2015-07-15,171,2015-09-13,231,60,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-027,Clinical Site 05,5,28,F,Hispanic,Treatment A,TRTA,Ongoing,2015-05-28,2016-04-29,338,Y,1,2015-07-18,52,2016-05-27,366,Y,Y,Screening,0,2015-05-28,1,2016-07-05,405,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-027,Clinical Site 05,5,28,F,Hispanic,Treatment A,TRTA,Ongoing,2015-05-28,2016-04-29,338,Y,1,2015-07-18,52,2016-05-27,366,Y,Y,Screening,0,2015-05-28,1,2016-07-05,405,49,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-027,Clinical Site 05,5,28,F,Hispanic,Treatment A,TRTA,Ongoing,2015-05-28,2016-04-29,338,Y,1,2015-07-18,52,2016-05-27,366,Y,Y,Visit 1,1,2015-07-16,50,2016-07-05,405,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-027,Clinical Site 05,5,28,F,Hispanic,Treatment A,TRTA,Ongoing,2015-05-28,2016-04-29,338,Y,1,2015-07-18,52,2016-05-27,366,Y,Y,Visit 1,1,2015-07-16,50,2016-07-05,405,63,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-027,Clinical Site 05,5,28,F,Hispanic,Treatment A,TRTA,Ongoing,2015-05-28,2016-04-29,338,Y,1,2015-07-18,52,2016-05-27,366,Y,Y,Visit 2,2,2015-09-17,113,2016-07-05,405,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-027,Clinical Site 05,5,28,F,Hispanic,Treatment A,TRTA,Ongoing,2015-05-28,2016-04-29,338,Y,1,2015-07-18,52,2016-05-27,366,Y,Y,Visit 2,2,2015-09-17,113,2016-07-05,405,57,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
05-027,Clinical Site 05,5,28,F,Hispanic,Treatment A,TRTA,Ongoing,2015-05-28,2016-04-29,338,Y,1,2015-07-18,52,2016-05-27,366,Y,Y,Visit 3,3,2015-11-13,170,2016-07-05,405,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-027,Clinical Site 05,5,28,F,Hispanic,Treatment A,TRTA,Ongoing,2015-05-28,2016-04-29,338,Y,1,2015-07-18,52,2016-05-27,366,Y,Y,Visit 3,3,2015-11-13,170,2016-07-05,405,49,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-027,Clinical Site 05,5,28,F,Hispanic,Treatment A,TRTA,Ongoing,2015-05-28,2016-04-29,338,Y,1,2015-07-18,52,2016-05-27,366,Y,Y,Visit 4,4,2016-01-01,219,2016-07-05,405,115,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-027,Clinical Site 05,5,28,F,Hispanic,Treatment A,TRTA,Ongoing,2015-05-28,2016-04-29,338,Y,1,2015-07-18,52,2016-05-27,366,Y,Y,Visit 6,6,2016-04-25,334,2016-07-05,405,71,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-028,Clinical Site 05,5,42,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-12-01,2016-09-28,303,Y,1,2016-01-31,62,2016-12-03,369,Y,N,Screening,0,2015-12-01,1,2016-09-04,279,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-028,Clinical Site 05,5,42,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-12-01,2016-09-28,303,Y,1,2016-01-31,62,2016-12-03,369,Y,N,Screening,0,2015-12-01,1,2016-09-04,279,49,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-028,Clinical Site 05,5,42,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-12-01,2016-09-28,303,Y,1,2016-01-31,62,2016-12-03,369,Y,N,Visit 1,1,2016-01-19,50,2016-09-04,279,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-028,Clinical Site 05,5,42,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-12-01,2016-09-28,303,Y,1,2016-01-31,62,2016-12-03,369,Y,N,Visit 1,1,2016-01-19,50,2016-09-04,279,117,RECIST 1.1,Best Overall Response (RECIST 1.1),SD,2,#92c5de
05-028,Clinical Site 05,5,42,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-12-01,2016-09-28,303,Y,1,2016-01-31,62,2016-12-03,369,Y,N,Visit 3,3,2016-05-15,167,2016-09-04,279,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-028,Clinical Site 05,5,42,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-12-01,2016-09-28,303,Y,1,2016-01-31,62,2016-12-03,369,Y,N,Visit 3,3,2016-05-15,167,2016-09-04,279,58,RECIST 1.1,Best Overall Response (RECIST 1.1),PD,5,#b2182b
05-028,Clinical Site 05,5,42,M,Other/Mixed,Treatment A,TRTA,Ongoing,2015-12-01,2016-09-28,303,Y,1,2016-01-31,62,2016-12-03,369,Y,N,Visit 4,4,2016-07-12,225,2016-09-04,279,54,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-029,Clinical Site 05,5,35,M,White,Placebo,PLACEBO,Ongoing,2015-10-02,2015-12-31,91,Y,1,2015-11-24,54,2016-10-09,374,Y,Y,Screening,0,2015-10-02,1,2016-01-09,100,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-029,Clinical Site 05,5,35,M,White,Placebo,PLACEBO,Ongoing,2015-10-02,2015-12-31,91,Y,1,2015-11-24,54,2016-10-09,374,Y,Y,Screening,0,2015-10-02,1,2016-01-09,100,62,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-029,Clinical Site 05,5,35,M,White,Placebo,PLACEBO,Ongoing,2015-10-02,2015-12-31,91,Y,1,2015-11-24,54,2016-10-09,374,Y,Y,Unscheduled 1.1,1.1,2015-12-03,63,2016-01-09,100,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-029,Clinical Site 05,5,35,M,White,Placebo,PLACEBO,Ongoing,2015-10-02,2015-12-31,91,Y,1,2015-11-24,54,2016-10-09,374,Y,Y,Unscheduled 1.1,1.1,2015-12-03,63,2016-01-09,100,37,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
05-030,Clinical Site 05,5,23,F,Hispanic,Treatment A,TRTA,Ongoing,2015-11-13,2016-06-06,207,Y,1,2016-01-02,51,2016-11-01,355,Y,Y,Screening,0,2015-11-13,1,2016-06-03,204,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),UN,1,#bdbdbd
05-030,Clinical Site 05,5,23,F,Hispanic,Treatment A,TRTA,Ongoing,2015-11-13,2016-06-06,207,Y,1,2016-01-02,51,2016-11-01,355,Y,Y,Screening,0,2015-11-13,1,2016-06-03,204,58,RECIST 1.1,Best Overall Response (RECIST 1.1),UN,3,#bdbdbd
05-030,Clinical Site 05,5,23,F,Hispanic,Treatment A,TRTA,Ongoing,2015-11-13,2016-06-06,207,Y,1,2016-01-02,51,2016-11-01,355,Y,Y,Visit 1,1,2016-01-10,59,2016-06-03,204,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-030,Clinical Site 05,5,23,F,Hispanic,Treatment A,TRTA,Ongoing,2015-11-13,2016-06-06,207,Y,1,2016-01-02,51,2016-11-01,355,Y,Y,Visit 1,1,2016-01-10,59,2016-06-03,204,51,RECIST 1.1,Best Overall Response (RECIST 1.1),CR,0,#2166ac
05-030,Clinical Site 05,5,23,F,Hispanic,Treatment A,TRTA,Ongoing,2015-11-13,2016-06-06,207,Y,1,2016-01-02,51,2016-11-01,355,Y,Y,Visit 2,2,2016-03-01,110,2016-06-03,204,0,PCWG SCHER PROSTATE CANCER 2016,PCWG3 Timepoint Response (Central assessment),NON-PD,0,#92c5de
05-030,Clinical Site 05,5,23,F,Hispanic,Treatment A,TRTA,Ongoing,2015-11-13,2016-06-06,207,Y,1,2016-01-02,51,2016-11-01,355,Y,Y,Visit 2,2,2016-03-01,110,2016-06-03,204,94,RECIST 1.1,Best Overall Response (RECIST 1.1),PR,1,#4393c3
